澳大利亚专利AU2007337826A1 Substituted heteroaryl pyridopyrimidone derivatives

专利PDF首页>>澳大利亚专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:

公开号:AU2007337826A1
申请号:U2007337826
申请日:2007-12-20
公开日:2008-07-03
发明作者:Aude Fayol；Thierry Gallet；Alistair Lochead；Mourad Saady；Corinne Veronique；Philippe Yaiche
申请人:Sanofi Aventis France；Mitsubishi Tanabe Pharma Corp；
IPC主号:C07D239-70

专利说明:
WO 2008/078196 PCT/IB2007/004409 1 SPECIFICATION SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES Technical Field The present invention relates to compounds that are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of neurodegenerative diseases caused by abnormal activity of GSK3p. Background Art GSK3p (glycogen synthase kinase 3p) is a proline directed serine, threonine kinase that plays an important role in the control of metabolism, differentiation and survival. It was initially identified as an enzyme able to phosphorylate and hence inhibit glycogen synthase. It was later recognized that GSK3p was identical to tau protein kinase 1 (TPK1), an enzyme that phosphorylates tau protein in epitopes that are also found to be hyperphosphorylated in Alzheimer's disease and in several taupathies. Interestingly, protein kinase B (AKT) phosphorylation of GSK3p results in a loss of its kinase activity, and it has been hypothesized that this inhibition may mediate some of the effects of neurotrophic factors. Moreover, phosphorylation by GSK3p of p-catenin, a protein involved in cell survival, results in its degradation by an ubiquitinilation dependent proteasome pathway. Thus, it appears that inhibition of GSK3p activity may result in neurotrophic activity. Indeed there is evidence that lithium, an uncompetitive inhibitor of GSK3p, enhances neuritogenesis in some models and also increases neuronal survival, through the induction of survival factors such as Bcl-2 and the inhibition of the expression of proapoptotic factors such as p53 and Bax. Recent studies have demonstrated that p-amyloid increases the GSK3P activity and tau protein phosphorylation. Moreover, this hyperphosphorylation as well as the neurotoxic effects of p-amyloid are blocked by lithium chloride and by a GSK3p antisense mRNA. These observations strongly suggest that GSK3p may be the link between the two major pathological processes in Alzheimer's disease: abnormal APP (Amyloid Precursor Protein) processing and tau protein hyperphosphorylation. Although tau hyperphosphorylation results in a destabilization of the neuronal cytoskeleton, the pathological consequences of abnormal GSK3p activity are, most likely, not only due to a pathological phosphorylation of tau protein because, WO 2008/078196 PCT/IB2007/004409 2 as mentioned above, an excessive activity of this kinase may affect survival through the modulation of the expression of apoptotic and antiapoptotic factors. Moreover, it has been shown that p-amyloid-induced increase in GSK3p activity results in the phosphorylation and, hence the inhibition of pyruvate dehydrogenase, a pivotal enzyme in energy production and acetylcholine synthesis. Altogether these experimental observations indicate that GSK3p may find application in the treatment of the neuropathological consequences and the cognitive and attention deficits associated with Alzheimer's disease, as well as other acute and chronic neurodegenerative diseases and other pathologies where GSK3p is deregulated (Nature reviews Vol.3, June 2004, p.479-487; Trends in Pharmacological Sciences Vol. 25 No. 9, Sept. 2004, p. 471-480; Journal of neurochemistry 2004, 89, 1313-1317; Medicinal Research Reviews, Vol. 22, No. 4, 373-384, 2002). The neurodegenerative diseases include, in a non-limiting manner, Parkinson's disease, tauopathies (e.g. Fronto temporal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy), Wilson's disease, Huntington's disease (The Journal of biological chemistry Vol. 277, No. 37, Issue of September 13, pp. 33791-33798, 2002), Prion disease (Biochem. J. 372, p.129-136, 2003) and other dementia including vascular dementia; acute stroke and other traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; amyotrophic lateral sclerosis (European Journal of Neuroscience, Vol. 22, pp. 301-309, 2005) peripheral neuropathies; retinopathies and glaucoma. Recent studies have also shown that inhibition of GSK3p results in neuronal differentiation of embryonic stem cells (ESC) and support the renewal of human and mouse ESCs and the maintenance of their pluripotency. This suggests that inhibitors of GSK3p could have applications in regenerative medicine (Nature Medicine 10, p. 55 - 63, 2004). Inhibitors of GSK3p may also find application in the treatment of other nervous system disorders, such as bipolar disorders (manic-depressive illness). For example lithium has been used for more than 50 years as a mood stabiliser and the primary treatment for bipolar disorder. The therapeutic actions of lithium are observed at doses (1-2 mM) where it is a direct inhibitor of GSK3p. Although the mechanism of action of lithium is unclear, inhibitors of GSK3p could be used to mimic the mood stabilising effects of lithium. Alterations in Akt-GSK3p signaling WO 2008/078196 PCT/IB2007/004409 3 have also been implicated in the pathogenesis of schizophrenia. In addition, inhibition of GSK3p could be useful in treating cancers, such as colorectal, prostate, breast, non-small lung carcinoma, thyroid cancer, T or B-cell leukaemia and several virus-induced tumours. For example, the active form of GSK3p has been shown to be elevated in the tumors of colorectal cancer patients and inhibition of GSK3p in colorectal cancer cells activates p53-dependent apoptosis and antagonises tumor growth. Inhibition of GSK3p also enhances TRAIL-induced apoptosis in prostate cancer cell lines. GSK3P also plays a role in the dynamics of the mitotic spindle and inhibitors of GSK3p prevent chromosome movement and lead to a stabilisation of microtubules and a prometaphase-like arrest that is similar to that observed with low doses of Taxol. Other possible applications for GSK3p inhibitors include therapy for non-insulin dependent diabetes (such as diabetes type II), obesity and alopecia. Inhibitors of human GSK3p may also inhibit pfGSK3, an ortholog of this enzyme found in Plasmodium falciparum, as a consequence they could be used for the treatment of malaria (Biochimica et Biophysica Acta 1697, 1,81- 196, 2004). Recently, both human genetics and animal studies have pointed out the role of Wnt/LPR5 pathway as a major regulator of bone mass accrual. Inhibition of GSK3P leads to the consequent activation of canonical Wnt signalling. Because deficient Wnt signalling has been implicated in disorders of reduced bone mass, GSK3p inhibitors may also be used for treating disorders of reduced bone mass, bone-related pathologies, osteoporosis. According to recent data, GSK3P inhibitors might be used in the treatment or prevention of Pemphigus vulgaris. Recent studies show that GSK3beta inhibitor treatment improves neutrophil and megakaryocyte recovery. Therefore, GSK3beta inhibitors will be useful for the treatment of neutropenia induced by cancer chemotherapy. Disclosure of the Invention An object of the present invention is to provide compounds useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of a disease caused by abnormal GSK3p activity, more particularly of neurodegenerative diseases. More specifically, the object is to provide novel compounds useful as an active ingredient of a medicament that enables WO 2008/078196 PCT/IB2007/004409 4 prevention and/or treatment of neurodegenerative diseases such as Alzheimer's disease. Thus, the inventors of the present invention have identified compounds possessing inhibitory activity against GSK3p. As a result, they found that compounds represented by the following formula (I) had the desired activity and were useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of the aforementioned diseases. The present invention thus provides as an object of the invention the pyrimidone derivatives represented by formula (1) or salts thereof, solvates thereof or hydrates thereof: R1 R3 R7 R6 N R21 n NN 0 z NN Y m )o R4 R5 (1) wherein: Y represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C 1
-
2 alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a C 1
.
6 alkyl group, a hydroxyl group, a C 1
.
6 alkoxy group, a C 1
-
2 perhalogenated alkyl group or an amino group; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted by a C 1
.
6 alkyl group, a C 1
.
6 alkoxy group or a halogen atom; R2 represents a 4-15 membered heterocyclic group, this group being optionally substituted by 1 to 4 substituents selected from a C 1
.
6 alkyl group, a halogen atom, a C 1
-
2 perhalogenated alkyl group, a C 1 _6 halogenated alkyl group, a hydroxyl group, a C 1
.
6 alkoxy group, a C 1
-
2 perhalogenated alkoxy group, a C 1
_
halogenated alkoxy group, a nitro, a cyano, an amino, a C 1
.
6 monoalkylamino group, a C 2
-
1 2 dialkylamino group, a S-(C1.e-alkyl) group, an 4-15 membered heterocyclic group, an aryl group, a 0-aryl group or a S-aryl group, the above- WO 2008/078196 PCT/IB2007/004409 5 mentioned groups being optionally substituted by 1 to 4 substituents selected from a C1.6 alkyl group, a halogen atom, a (C1-6) alkoxy group, a C(O)O (C 1
.
6 -alkyl) or a C(0)0 (aryl) group; R3 represents a hydrogen atom, a C 1
..
6 alkyl group or a halogen atom; R4 and R5 represent, each independently, a hydrogen atom, a C 1
.
6 alkyl group, optionally substituted by 1 to 4 substituents selected from a halogen atom, a phenyl group, a hydroxyl group or a C1.. alkoxy group; R6 represents a hydrogen atom, a C1.6 alkyl group optionally substituted by a halogen atom or a cycloalkyl group, or a halogen atom; R7 represents a hydrogen atom or a C1.6 alkyl group; n represents 0 to 3; m represents 0 to 1; o represents 0 to 2; in the form of a free base or of an addition salt with an acid. According to another aspect of the present invention, there is provided a medicament comprising as an active ingredient a substance selected from the group consisting of the pyrimidone derivatives represented by formula (I) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof. As preferred embodiments of the medicament, there are provided the aforementioned medicament which is used for preventive and/or therapeutic treatment of diseases caused by abnormal GSK3p activity, and the aforementioned medicament which is used for preventive and/or therapeutic treatment of neurodegenerative diseases and in addition other diseases such as: Non-insulin dependent diabetes (such as diabetes type II ) and obesity; malaria, bipolar disorders (manic depressive illness); schizophrenia; alopecia or cancers such as colorectal, prostate, breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukaemia, several virus-induced tumours. The medicament could also find an application in regenerative medicine, Pemphigus vulgaris, neutropenia and bone diseases. As further embodiments of the present invention, there are provided the aforementioned medicament wherein the diseases are neurodegenerative diseases and are selected from the group consisting of Alzheimer's disease, Parkinson's disease, tauopathies (e.g. Fronto temporal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy), Wilson's disease, Huntington's disease, Prion disease and other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; amyotrophic lateral sclerosis; peripheral neuropathies; retinopathies and WO 2008/078196 PCT/IB2007/004409 6 glaucoma, and the aforementioned medicament in the form of pharmaceutical composition containing the above substance as an active ingredient together with one or more pharmaceutical additives. As further embodiments of the present invention, there are provided the aforementioned medicament wherein the bones diseases are osteoporosis. The present invention further provides an inhibitor of GSK3p activity comprising as an active ingredient a substance selected from the group consisting of the pyrimidone derivatives of formula (1) and the salts thereof, and the solvates thereof and the hydrates thereof. According to further aspects of the present invention, there is provided a method for preventive and/or therapeutic treatment of neurodegenerative diseases caused by abnormal GSK3p activity, which comprises the step of administering to a patient a preventively and/or therapeutically effective amount of a substance selected from the group consisting of pyrimidone derivatives of formula (1) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof; and a use of a substance selected from the group consisting of the pyrimidone derivatives of formula (1) and the physiologically acceptable salts thereof, and the solvates thereof and the hydrates thereof for the manufacture of the aforementioned medicament. As used herein, the C1-6 alkyl group represents a straight or branched or cyclo alkyl group having 1 to 6 carbon atoms, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, isopentyl group, neopentyl group, 1,1 dimethylpropyl group, n-hexyl group, isohexyl group, and the like. The 4-15 membered heterocyclic group represents an unsaturated, fully saturated or partially saturated mono- or polycyclic group (for example 4 to 10 members) containing carbons atoms and one to seven heteroatoms chosen from N, 0, and S. Examples of heterocyclic groups include pyridine, pyrindine, pyrimidine, pyrazine, pyridazine, triazine, pyrrole, furane, thiophene, pyrazole, imidazole, triazole, tetrazole, oxazole, isoxazole, oxadiazole, thiazole, isothiazole, thiadiazole pyrrolopyrrole, pyrroloimidazole, pyrrolopyrazole, pyrrolotriazole, imidazoimidazole, imidazopyrazole, imidazotriazole, isoxazole, oxadiazole, quinoline, isoquinoline, cinnoline, phthalazine, quinoxaline, quinazoline, naphthyridine, benzotriazine, pyridopyrimidine, pyridopyrazine, pyridopyridazine, pyridotriazine, pyrimidopyrimidine, pyrimidopyrazine, pyrimidopyridazine, pyrimidotriazine, pyrazinopyrazine, pyrazinopyridazine, pyrazinotriazine, WO 2008/078196 PCT/IB2007/004409 7 pyridazinopyridazine, pyridazinotriazine, indole, isoindole, benzimidazole, indazole, indolizine, benzofuran, isobenzofuran, benzothiophene, benzo[c]thiophen, pyrrolopyridine, imidazopyridine, pyrazolopyridine, triazolopyridine, tetrazolopyridine, pyrrolopyrimidine, imidazopyrimidine, pyrazolopyrimidine, triazolopyrimidine, tetrazolopyrimidine, pyrrolopyrazine, imidazopyrazine, pyrazolopyrazine, triazolopyrazine, tetrazolopyrazine, pyrrolopyridazine, imidazopyridazine, pyrazolopyridazine, triazolopyridazine, tetrazolopyridazine, pyrrolotriazine, imidazotriazine, pyrazolotriazine, triazolotriazine, tetrazolotriazine, furopyridine, furopyrimidine, furopyrazine, furopyridazine, furotriazine, oxazolopyridine, oxazolopyrimidine, oxazolopyrazine, oxazolopyridazine, oxazolotriazine, isoxazolopyridine, isoxazolopyrimidine, isoxazolopyrazine, isoxazolopyridazine, isoxazolotriazine, oxadiazolopyridine, oxadiazolopyrimidine, oxadiazolopyrazine, oxadiazolopyridazine, oxadiazolotriazine, benzoxazole, benzisoxazole, benzoxadiazole, thienopyridine, thienopyrimidine, thienopyrazine, thienopyridazine, thienotriazine, thiazolopyridine, thiazolopyrimidine, thiazolopyrazine, thiazolopyridazine, thiazolotriazine, isothiazolopyridine, isothiazolopyrimidine, isothiazolopyrazine, isothiazolopyridazine, isothiazolotriazine, thiadiazolopyridine, thiadiazolopyrimidine, thiadiazolopyrazine, thiadiazolopyridazine, thiadiazolotriazine, benzothiazole, benzoisothiazole, benzothiadiazole, benzotriazole, benzodioxepine, benzodioxane, benzodioxine, benzodioxole, diazepane. These heterocycles can exist also in a partially or fully saturated form, for example as an illustration dihydrobenzofuran, tetrahydroquinoline etc... The C1.6 alkoxy group represents an alkyloxy group having 1 to 4 carbon atoms for example, methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, and the like; The halogen atom represents a fluorine, chlorine, bromine or iodine atom; The C 1
-
2 perhalogenated alkyl or alkoxy group represents an alkyl or alkoxy group wherein all the hydrogen atoms have been substituted by a halogen atom, for example a CF 3 or C 2
F
5 ; O-CF 3 or O-C 2
F
5 ; The C 1 .6 halogenated alkyl group represents an alkyl group wherein at least one hydrogen has not been substituted by an halogen atom; The C 1
.
6 halogenated alkoxy group represents an alkoxy group wherein at least one hydrogen of the alkyl group has not been substituted by an halogen atom; The C 1
.
6 monoalkylamino group represents an amino group substituted by one C 1
.
6 alkyl group, for example, methylamino group, ethylamino group, WO 2008/078196 PCT/IB2007/004409 8 propylamino group, isopropylamino group, butylamino group, isobutylamino group, tert-butylamino group, pentylamino group, isopentylamino group and the like; The C 2
-
1 2 dialkylamino group represents an amino group substituted by two C 1 .e alkyl groups, for example, dimethylamino group, ethylmethylamino group, diethylamino group, methylpropylamino group and diisopropylamino group and the like; The aryl group represents an aromatic mono or bicyclic ring (for example 6 to 10 members) such as phenyl, naphthyl, pentalene, azulene, heptalene, indacene, acenaphthylene, benzocyclooctatretraene, bicyclo[4.2.0]octa-1,3,5,7 tetraene, bicyclo[5. 1.0]octa-1,3,5,7-tetraene, bicyclo[6.2.0]deca-1,3,5,7,9 pentaene. A leaving group L represents a group which could be easily cleaved and substituted, such a group may be for example a tosyl, a mesyl, a bromide and the like. The compounds represented by the aforementioned formula (1) may form a salt. Examples of the salt include, when an acidic group exists, salts of alkali metals and alkaline earth metals such as lithium, sodium, potassium, magnesium, and calcium; salts of ammonia and amines such as methylamine, dimethylamine, trimethylamine, dicyclohexylamine, tris(hydroxymethyl)aminomethane, NN bis(hydroxyethyl)piperazine, 2-amino-2-methyl-1-propanol, ethanolamine, N methylglucamine, and L-glucamine; or salts with basic amino acids such as lysine, S-hydroxylysine, and arginine. The base-addition salts of acidic compounds are prepared by standard procedures well known in the art. When a basic group exists, examples include salts with mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid; salts with organic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, acetic acid, propionic acid, tartaric acid, fumaric acid, maleic acid, malic acid, oxalic acid, succinic acid, citric acid, benzoic acid, mandelic acid, cinnamic acid, lactic acid, glycolic acid, glucuronic acid, ascorbic acid, nicotinic acid, and salicylic acid; or salts with acidic amino acids such as aspartic acid, and glutamic acid. The acid-addition salts of the basic compounds are prepared by standard procedures well known in the art which include, but are not limited thereto, dissolving the free base in an aqueous alcohol solution containing the appropriate WO 2008/078196 PCT/IB2007/004409 9 acid and isolating the salt by evaporating the solution, or by reacting the free base and an acid in an organic solvent, in which case the salt separates directly, or is precipitated with a second organic solvent, or can be obtained by concentration of the solution. The acids which can be used to prepare the acid-addition salts include preferably those which produce, when combined with the free base, pharmaceutically-acceptable salts, that is, salts whose anions are relatively innocuous to the animal organism in pharmaceutical doses of the salts, so that the beneficial properties inherent in the free base are not compromised by side effects ascribable to the anions. Although medicinally acceptable salts of the basic compounds are preferred, all acid-addition salts are within the scope of the present invention. In addition to the pyrimidone derivatives represented by the aforementioned formula (1) and salts thereof, their solvates and hydrates also fall within the scope of the present invention. The pyrimidone derivatives represented by the aforementioned formula (1) may have one or more asymmetric carbon atoms. As for the stereochemistry of such asymmetric carbon atoms, they may independently be in either (R) and (S) configuration, and the derivative may exist as stereoisomers such as optical isomers, or diastereoisomers. Any stereoisomers in pure form, any mixtures of stereoisomers, racemates and the like fall within the scope of the present invention. In a first embodiment of the invention, there is provided compounds wherein R1 represents an unsubstituted 4-pyridine ring or unsubstituted 4-pyrimidine ring, in the form of a free base or of an addition salt with an acid. In a second embodiment of the invention, there is provided compounds of formula (1) wherein R4 and R5 represent a hydrogen atom, in the form of a free base or of an addition salt with an acid. In a third embodiment of the invention, there is provided compounds of formula (1) wherein (m+o) represents 2 or 3, in the form of a free base or of an addition salt with an acid In an another embodiment of the invention, there is provided compounds of formula (1) wherein R2 represents a benzotriazole group, quinoxaline group, WO 2008/078196 PCT/IB2007/004409 10 benzodioxepine group, benzodioxane group, benzodioxine group, benzodioxole group, indole group, pyridine group, pyrindine group, quinoline group, pyridazine group, isoquinoline group, pyrimidine group, naphthyridine group, imidazopyridine group, cinnoline group or benzofuran group and where the above-mentioned group being optionally substituted by 1 to 4 substituents selected from a C 1
.
6 alkyl group, a halogen atom, a C 1 .6 alkoxy group, a C1- 2 perhalogenated alkoxy group, an amino, a S-C 1
.
6 -alkyl group, a furan group, a thiophene group, a [1,4]diazepane, a phenyl group, a 0-phenyl group or a S-phenyl group, the above mentioned groups being optionally substituted by 1 to 4 substituents selected from a C 1
.
6 alkyl group, a halogen atom, a C 1
.
6 alkoxy group, or a C(O)O C 1
.
6 -alkyl in the form of a free base or of an addition salt with an acid. In another embodiment of the invention, there is provided compounds of formula (I) wherein R6 represents a hydrogen atom, a methyl or an ethyl group, in the form of a free base or of an addition salt with an acid. In another embodiment of the invention, there is provided compounds of formula (1) wherein n represents 0, in the form of a free base or of an addition salt with an acid. In another embodiment of the invention, there is provided compounds of formula (I) wherein Z represents a bond, in the form of a free base or of an addition salt with an acid. In another embodiment of the invention, there is provided compounds of formula (1) wherein Y represents an oxygen atom, in the form of a free base or of an addition salt with an acid. In another embodiment of the invention, there is provided compounds of formula (1) wherein R4 and R5 represent a hydrogen atom; (m+o) represents 2 or 3; R2 represents a benzotriazole group, quinoxaline group, benzodioxepine group, benzodioxane group, benzodioxine group, benzodioxole group, indole group, pyridine group, pyrindine group, quinoline group, pyridazine group, isoquinoline group, pyrimidine group, naphthyridine group, imidazopyridine group, cinnoline group or benzofuran group and where the above-mentioned group being optionally substituted by 1 to 4 substituents selected from a C 1
.
6 alkyl group, a halogen atom, a C1.6 alkoxy group, a C1-2 perhalogenated alkoxy group, an WO 2008/078196 PCT/IB2007/004409 11 amino, a S-C1.
6 -alkyl group, a furan group, a thiophene group, a [1,4]diazepane, a phenyl group, a 0-phenyl group or a S-phenyl group, the above-mentioned groups being optionally substituted by 1 to 4 substituents selected from a C 1 .6 alkyl group, a halogen atom, a C 1
.
6 alkoxy group, or a C(O)O C 1
.
6 -alkyl; R6 represents a hydrogen atom, a methyl or an ethyl group; n represents 0; Z represents a bond, and Y represents an oxygen atom, in the form of a free base or of an addition salt with an acid. Examples of compounds of the present invention are shown in table 1, table 2 and table 3 hereinafter. However, the scope of the present invention is not limited by these compounds. The nomenclature is given according to IUPAC rules. A further object of the present invention includes the group of compounds of table 1 of formula as defined hereunder: 1. (+/-) 2,2-Dimethyl-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyridin-4 yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 2. (+/-)1-Methyl-1H-benzotriazole-5-carboxylic acid (4-oxo-2-pyridin-4-yl-6,7,8,9 tetrahyd ro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 3. (+/-) Quinoxaline-6-carboxylic acid (4-oxo-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H pyrido[1,2-a]pyrimidin-9-yl)-amide 4. (+/-) 2,3-Dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyrimidin-4-yl-6,7,8,9 tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 5. (+/-)2,2-Difluoro-benzo[1,3]dioxole-4-carboxylic acid (4-oxo-2-pyridin-4-yl 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 6. (+/-) 3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (4-oxo-2-pyridin 4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 7. (+/-) Benzofuran-2-carboxylic acid (4-oxo-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H pyrido[1,2-a]pyrimidin-9-yl)-amide WO 2008/078196 PCT/IB2007/004409 12 8. (+/-) 2,2-Dimethyl-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyrimidin 4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 9. (+/-) 8-Amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid (4-oxo 2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 10. (+/-) 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (4-oxo-2-pyrimidin-4-yi 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 11. (+/-) 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (4-oxo-2-pyridin-4-yl 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 12. (+/-) 2,3-Dihydro-benzofuran-5-carboxylic acid (4-oxo-2-pyridin-4-yl-6,7,8,9 tetrahydro-4H-pyrido[ 1,2-a]pyrimidin-9-yl)-amide 13. (+/-) 8-Amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid (4 oxo-2-pyridin-4-yI-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 14. (+/-) 1-Methyl-1H-indole-3-carboxylic acid (4-oxo-2-pyridin-4-yl-6,7,8,9 tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 15. (+/-) 2-Methoxy-N-(4-oxo-2-pyridin-4-yl-6,7,8,9-tetrahyd ro-4H-pyrido[ 1,2 a]pyrimidin-9-yl)-nicotinamide 16. (+/-) 6,7-Dihydro-5H-[1]pyrindine-6-carboxylic acid (4-oxo-2-pyridin-4-yl 6,7,8,9-tetrahydro-4H-pyrido[ 1,2-a]pyrimidin-9-yl)-amide 17. (+/-) 2-Methoxy-N-(4-oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2 a]pyrimidin-9-yl)-nicotinamide 18. (+/-) 2,6-Dimethoxy-N-(4-oxo-2-pyrimidin-4-yl-6,7,8,9 -tetrahyd ro-4H pyrido[1,2-a]pyrimidin-9-yI)-nicotinamide 19. (+/-) N-(4-Oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9 yl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide 20. (+/-) 2-Fluoro-N-(4-oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[ 1,2 a]pyrimidin-9-yl)-nicotinamide WO 2008/078196 PCT/1B2007/004409 13 21. (+/-) N-(4-Oxo-2-pyrimidin-4-yI-6 ,7,8,9-tetrahydro-4H-pyrido[1 ,2-a]pyrimid in-9 yI)-2-p-tolyloxy-n icotinamide 22. (+/-) 2-(4-Ch lo ro-p hen oxy)- N-(4-oxo-2-pyri mid in -4-yI-6,7 ,8,9 -tetra hyd ro-4H pyrido[1 ,2-a]pyrimidin-9-yI)-nicotinamide 23. (+/-) 2-Methyls ulfa nyl- N-(4-oxo-2-pyri mid in -4-yI-6,7,8 ,9 -tetra hyd ro-4 H pyrido[1 ,2-a]pyrimidin-9-yI)-nicotinamide 24. (+/-) 5-Fu ran-2-yI-N-(4-oxo-2-pyrimid in-4-yI-6 ,7,8,9-tetrahyd ro-4H-pyrido[1 ,2 a]pyrimidin-9-yi)-nicotinamide 25. (+/-) 5-(2-Methoxy-phenyl)-N-(4-oxo-2-pyrimidin-4-yI-6 ,7 ,8,9-tetrahydro-4H pyrido[1 ,2-a]pyrimidin-9-yI)-nicotinamide 26. (+/-) 5-(3,4-Dimethoxy-phenyl)-N-(4-oxo-2-pyrimidin-4-yI-6 ,7 ,8,9-tetrahydro 4H-pyrido[1 ,2-a]pyrimid in-9-yI)-nicotinamide 27. (+/-) Quinoline-3-carboxylic acid (4-oxo-2-pyrimid in-4-yI-6 ,7 ,8,9-tetrahydro 4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide 28. (+/-) N-(4-Oxo-2-pyrimidin-4-yI-6,7 ,8,9-tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9 yI)-6-thiophen-2-yI-nicotinamide 29. (+/-) 4-[5-(4-Oxo-2-py rim id in-4-yi-6 ,7,8 1 9-tetra hyd ro-4 H-py rido [1, ,2-a]pyri mid i n 9-ylcarbamoyl)-pyridin-2-y]-[1 ,4]diazepane-1 -carboxylic acid tert-butyl ester 30. (+/-) 6-Methyl-N-(4-oxo-2-pyrimidin-4-yI-6 ,7,8,9-tetrahydro-4H-pyridoll ,2 a~pyrimidin-9-yI)-nicotinamide 31. (+/-) N-(4-Oxo-2-pyrimidin-4-yI-6 ,7 ,8,9-tetrahyd ro-4H-pyrido[1 ,2-a]pyrimidin-9 yI)-2-propylsulfanyl-nicotinamide 32. (+/-) N-(4-Oxo-2-pyrimidin-4-yI-6 ,7,8,9-tetrahyd ro-4H-pyrido[1 ,2-a]pyrimidin-9 yI)-n icotinamide 33. (+/-) 6-Chloro-N-(4-oxo-2-pyrimidin-4-yI-6,7,8, 9-tetrahydro-4H-pyrido[1 ,2- WO 2008/078196 PCT/1B2007/004409 14 a]pyrimidin-9-yI)-nicotinamide 34. (+/-) 2-Methoxy-N-(9-methyl-4-oxo-2-pyrimidin-4-yI-6,7 ,8,9-tetrahyd ro-4H pyrido[1 ,2-a]pyrimidin-9-yI)-nicotinamide 35. (+/-) 4-Methoxy-pyridine-2-carboxylic acid (4-oxo-2-py rim id in-4-yI1-6,7 .8,9 tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide 36. (+/-) 3,6-Dimethoxy-pyridazine-4-carboxylic acid (4-oxo-2-pyrimidin-4-yi 6,7,8,9-tetrahyd ro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide 37. (+/-) Pyridine-2-carboxylic acid (4-oxo-2-py rim id in-4-yI-6,7, 8,9-tetra hyd ro-4 H pyrido[1 ,2-a]pyrimidin-9-yI)-amide 38. (+/-) 6-Methoxy-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI-6,7 ,8 ,9 tetra hyd ro-4 H-pyrid o[1, ,2-a] pyrim id in-9-yI)-am ide 39. (+/-) 4-Methoxy-quinoline-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI-6,7 ,8 ,9 tetrahydro-4H-pyrido[1 ,2-a]pyrimid in-9-yI)-amide 40. (+/-) Isoquinoline-1 -carboxylic acid (4-oxo-2-pyrimidin-4-yI-6,7 ,8,9-tetrahyd ro 4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide 41. (+/-) 5-Chloro-2-methylsulfanyl-pyrimidine-4-carboxylic acid (9-methyl-4-oxo 2-pyrimidin-4-yI-6,7 ,8,9-tetrahyd ro-4H-pyrido[1 ,2-a]pyrimid in-9-yI)-amide 42. (+/-) [1 ,6]Naphthyridine-5-carboxylic acid (4-oxo-2-pyrimid in-4-yI-6,7 ,8 ,9 tetra hyd ro-4 H-pyrid o[1, ,2-a] pyrim idin -9-yI)-am ide 43. (+/-) 6-Chloro-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI-6,7 ,8,9 tetrahyd ro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide 44. (+/-) [1, 5jNaphthyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI-6 ,7,8 ,9 tetra hyd ro-4H-pyridojl ,2-a]pyrimid in-9-yi)-amide 45. (+/-) 6-(2 ,6-Dimethoxy-phenyl)-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin 4-yI-6,7, 8,9-tetrahydro-4H-pyrido[1 ,2-a]pyrimid in-9-yI)-amide WO 2008/078196 PCT/1B2007/004409 15 46. (+/-) 6-(2-Fluoro-phenyl)-pyridine-2-carboxyic acid (4-oxo-2-pyrimidin-4-yi 6,7,8 ,9-tetrahydro-4H-pyrido[1,2-alpyrimid in-9-yI)-amide 47. (+/-) 8-Amino-7-chloro-2 ,3-dihyd ro-benzo[1 ,4]dioxine-5-carboxylic acid (9 methyl-4-oxo-2-pyrimid in-4-yI-6,7,8,9-tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9 yI)-amide 48. (+/-) 3 ,6-Dimethoxy-pyridazine-4-carboxylic acid (9-methyl-4-oxo-2-pyrimid in 4-yI-6 ,7,8 ,9-tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide 49. (+/-) 2,2-Dimethyl-2 ,3-dihydro-benzofuran-7-carboxylic acid (9-methyl-4-oxo 2-pyrimid in-4-yI-6 ,7 ,8,9-tetrahyd ro-4H-pyrido[1 ,2-a]pyrimid in-9-yI)-amide 50. (+/-) 6-Fluoro-4H-benzo[1 ,3]dioxine-8-carboxylic acid (9-methyl-4-oxo-2 pyrimid in-4-yI-6,7,8,9-tetrahyd ro-4H-pyrido[1 ,2-a]pyrimid in-9-yI)-amide 51. (+/-) [1 ,5]Naphthyridine-2-carboxylic acid (9-methyl-4-oxo-2-pyrimidin-4-yI 6,7,8, 9-tetrahyd ro-4 H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide 52. (+/-) 2 ,3-Dihydro-benzofu ran-7-carboxylic acid (9-methyl-4-oxo-2-pyrimid in-4 yI-6 ,7,8,9-tetrahydro-4H-pyrido[1 ,2-a]pyrimid in-9-yI)-amide 53. (+/-) Pyridine-2-carboxylic acid (9-methyl-4-oxo-2-pyrimidin-4-yI-6 ,7,8,9 tetra hyd ro-4H-pyrido[ 1,2-ajpyrimid in-9-yI)-am ide 54. (+/-) 6-Chioro-pyridine-2-carboxylic acid (9-methyl-4-oxo-2-pyrimidin-4-yI 6,7,8, 9-tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide 55. (+/-) [1 ,6]Naphthyridine-5-carboxylic acid (9-methyl-4-oxo-2-pyrimidin-4-yI 6,7,8,9-tetra hyd ro-4 H-pyrido [1, ,2-alpyri mid in-9-yI)-a mid e 56. (-) N-(9-Methyl-4-oxo-2-pyrimid in-4-yI-6,7,8,9-tetrahydro-4H-pyrido[1 ,2 a]pyrimidin-9-yI)-nicotinamide 57. (+/-) 5-Bromo-benzofuran-2-carboxylic acid (9-methyl-4-oxo-2-pyrimidin-4-yI 6,7,8,9-tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide 58. (+) 6-(2-Fluoro-phenyl)-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI- WO 2008/078196 PCT/IB2007/004409 16 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 59. (-) 6-(2-Fluoro-phenyl)-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 60. (+) 2-Methoxy-N-(9-methyl-4-oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H pyrido[1,2-a]pyrimidin-9-yl)-nicotinamide 61. (-) 2-Methoxy-N-(9-methyl-4-oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H pyrido[1,2-a]pyrimidin-9-yl)-nicotinamide 62. (+) [1,5]Naphthyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI-6,7,8,9 tetrahyd ro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 63. (-) [1,5]Naphthyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl-6,7,8,9 tetrahyd ro-4H-pyrido[1 ,2-a]pyrimidin-9-yl)-amide A further object of the present invention includes the group of compounds of table 2 of formula as defined hereunder: 1. (+/-) 2,2-Dimethyl-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyridin-4 yl-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidin-8-yl)-amide 2. (+/-) 1-Methyl-1H-benzotriazole-5-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6,7,8 tetrahydro-pyrrolo[1,2-a]pyrimidin-8-yl)-amide 3. (+/-) 8-Amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid (4-oxo 2-pyridin-4-yl-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidin-8-yl)-amide 4. (+/-) 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (4-oxo-2-pyridin-4-yl 4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidin-8-yI)-amide 5. (+/-) Quinoxaline-6-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6,7,8-tetrahydro pyrrolo[1,2-a]pyrimidin-8-yl)-amide 6. (+/-) 2,3-Dihydro-benzofuran-5-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6,7,8 tetrahydro-pyrrolo[1,2-alpyrimidin-8-yl)-amide WO 2008/078196 PCT/1B2007/004409 17 7. (1) 1-Methyl-I H-indole-3-carboxylic acid (4-oxo-2-pyridin-4-yI-4 ,6,7 ,8 tetra hyd ro-pyrrolo[1, ,2-a] pyri mid in-8-yl)-am ide 8. (+/-) 5-Bromo-2, 3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyrid in-4-yi 4,6,7,8-tetrahydro-pyrroo[1 ,2-a]pyrim idin-8-yl)-amide 9. (+/-) -2 ,3-Dihydro-benzofuran-2-carboxylic acid (4-oxo-2-pyridin-4-yI-4,6 ,7,8 tetra hyd ro-pyrrolofi 1,2-a] pyri mid in-8-yl)-am ide 10. (+1-) 6,7-Dihydro-5 H-[I ]pyrindine-6-carboxylic acid (4-oxo-2-py rid in-4-yl 4,6,7,8-tetrahydro-pyrroo[1 ,2-a]pyrim idin-8-yI)-amide 11. (+/-) Benzofuran-2-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6 ,7 ,8-tetrahydro pyrrolo[1 ,2-a]pyrimidin-8-yl)-amide 12. (+/-) [1 ,5]Naphthyrid ine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI-4,6 ,7,8 tetra hyd ro-pyrrolo[I ,2-a]pyrim id in-8-yI)-am ide 13. (-) 2-Methoxy-N-(4-oxo-2-pyrimidin-4-y-4,6 ,7 1 8-tetrahydro-pyrrolo[1 ,2 a]pyrimidin-8-yI)-n icotinamide 14. (-) 5-Chloro-2-methylsulfany-pyrimid ine-4-carboxylic acid (4-oxo-2 pyrimidin-4-yI-4,6 ,7,8-tetrahyd ro-pyrrolo[1 ,2-a]pyrimidin-8-yl)-amide 15. (+/-) Isoquinoline-1 -carboxylic acid (4-oxo-2-py rim id in-4-yI-4,6 ,7 ,8-tetra hyd ro pyrrolo[I ,2-a]pyrimidin-8-yI)-amide 16. (+/-) 2-Meth oxy- N-(4-oxo-2-py rid in -4-yI-4,6,7,8-tetra hyd ro-pyrro lo [1, 2 alpyrimid in-8-yI)-n icotinamide 17. (+/-) 5-Chloro-2-methylsu lfanyl-pyrimidine-4-carboxylic acid (4-oxo-2-pyridin-4 yI-4,6,7 ,8-tetrahydro-pyrrolo[1 ,2-a]pyrimidin-8-yI)-amide 18. (+/-) Isoquinoline-I -carboxylic acid (4-oxo-2-pyrid in-4-yI-4 ,6 ,7,8-tetrahydro pyrroloji ,2-a]pyrimidin-8-yI)-amide 19. (+/-) Pyridine-2-carboxylic acid (4-oxo-2-pyrimid in-4-yI-4,6 ,7,8-tetrahydro pyrrolo[I ,2-a]pyrimidin-8-yI)-amide WO 2008/078196 PCT/IB2007/004409 18 20. (+/-) 6-Ch loro-pyridine-2-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6,7,8 tetrahydro-pyrrolo[1,2-a]pyrimidin-8-yI)-amide 21. (+/-) [1,5]Naphthyridine-2-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6,7,8 tetrahydro-pyrrolo[1,2-a]pyrimidin-8-yl)-amide A further object of the present invention includes the group of compounds of table 3 of formula as defined hereunder: 1. (+/-) 8-Amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid (4-oxo 2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 2. (+/-) 2-Methoxy-N-(4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-yl)-nicotinamide 3. (+/-) 5-Bromo-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 4. (+/-) 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 5. (+/-) 5-Chloro-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 6. (+/-) 2,3-Dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-10-yl)-amide 7. (+/-) 2,2-Dimethyl-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyrimidin 4-yi-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 8. (+/-) 2,2-Dimethyl-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyridin-4 yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 9. (+/-) 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (4-oxo-2-pyridin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1O-yl)-amide 10. (+/-) 5-Chloro-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyridin-4-yl- WO 2008/078196 PCT/IB2007/004409 19 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yi)-amide 11. (+/-) 2,3-Dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyridin-4-yi 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yi)-amide 12. (+/-) 8-Amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid (4-oxo 2-pyridin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yi)-amide 13. (+/-) 2-Methoxy-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-y)-nicotinamide 14. (+) 2-Methoxy-N-(4-oxo-2-pyrimidin-4-yI-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-yl)-nicotinamide 15. (-) 2-Methoxy-N-(4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-y)-nicotinamide 16. (+/-) 2,6-Dimethoxy-N-(4-oxo-2-pyridin-4-y-4,6,7,8,9,10-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 17. (+/-) N-(4-Oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin-10 yl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide 18. (+/-) 2-Fluoro-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[ 1,2 a]azepin-1 0-yl)-nicotinamide 19. (+/-) 2-Methylsulfanyl-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 20. (+/-) N-(4-Oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin-10 yI)-2-p-tolyloxy-nicotinamide 21. (+/-) 2-(4-Chloro-phenoxy)-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9, 10-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 22. (+/-) 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid (4-oxo-2-pyridin-4-yi 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-10-yl)-amide WO 2008/078196 PCT/IB2007/004409 20 23. (+/-) N-(4-Oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin-10 yl)-6-thiophen-2-yl-nicotinamide 24. (+/-) 6-Methyl-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-10-yl)-nicotinamide 25. (+/-) 5-Furan-2-yl-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-yi)-nicotinamide 26. (+/-) 5-(2-Methoxy-phenyl)-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 27. (+/-) 5-(3,4-Dimethoxy-phenyl)-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 28. (+/-) Quinoline-3-carboxylic acid (4-oxo-2-pyridin-4-yI-4,6,7,8,9,10-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-amide 29. (+/-) 4-[5-(4-Oxo-2-pyridin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin 10-ylcarbamoyl)-pyridin-2-yl]-[1,4]diazepane-1-carboxylic acid tert-butyl ester 30. (+/-) 5-(4-Bromo-phenyl)-N-(4-oxo-2-pyridin-4-yI-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 31. (+/-) N-(4-Oxo-2-pyridin-4-yI-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin-10 yl)-nicotinamide 32. (+/-) 6-Chloro-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-y)-nicotinamide 33. (+/-) 2-Chloro-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-yi)-nicotinamide 34. (+/-) N-(4-Oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin-10 yl)-2-phenylsulfanyl-nicotinamide 35. (+/-) N-(4-Oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin-10 yl)-2-propylsulfanyl-nicotinamide WO 2008/078196 PCT/IB2007/004409 21 36. (+/-) 2-(4-Chloro-phenylsulfanyl)-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yi)-nicotinamide 37. (+/-) 4-Methyl-2-phenyl-pyrimidine-5-carboxylic acid (4-oxo-2-pyrimidin-4-yi 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yi)-amide 38. (+/-) Pyrimidine-5-carboxylic acid (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 39. (+/-) 5-Chloro-2-methylsulfanyl-pyrimidine-4-carboxylic acid (4-oxo-2 pyrimidin-4-yl-4,6,7,8,9, 1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 40. (+/-) Pyridazine-4-carboxylic acid (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yi)-amide 41. (+/-) 6-Phenyl-pyrimidine-4-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 42. (+/-) Cinnoline-4-carboxylic acid (4-oxo-2-pyrimidin-4-y-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 43. (+/-) 3,6-Dimethoxy-pyridazine-4-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-ajazepin-1 0-yi)-amide 44. (+/-) Isoquinoline-1-carboxylic acid (4-oxo-2-pyridin-4-yI-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 45. (+/-) 3-Phenyl-cinnoline-4-carboxylic acid (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 46. (+/-) [1,6]Naphthyridine-5-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 47. (+/-) [1,5]Naphthyridine-2-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 48. (+/-) [1,6]Naphthyridine-5-carboxylic acid (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10- WO 2008/078196 PCT/IB2007/004409 22 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 49. (+/-) [1,5]Naphthyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 50. (+/-) 4-Methoxy-quinoline-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 51. (+/-) Isoquinoline-1-carboxylic acid (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 52. (+/-) Pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 53. (+/-) 6-Chloro-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 54. (+/-) 4-Methoxy-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yi-4,6,7,8,9, 10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 55. (+/-) 3,5-Difluoro-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 56. (+/-) 6-(2,6-Dimethoxy-phenyl)-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4 yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-ajazepin-1 0-yl)-amide 57. (+/-) 4-Methyl-2-phenyl-pyrimidine-5-carboxylic acid (4-oxo-2-pyridin-4-yi 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 58. (+/-) 3-Phenyl-cinnoline-4-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 59. (+/-) 3,6-Dimethoxy-pyridazine-4-carboxylic acid (4-oxo-2-pyridin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 60. (+/-) 2-Methyl-4-phenyl-pyrimidine-5-carboxylic acid (4-oxo-2-pyridin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide WO 2008/078196 PCT/IB2007/004409 23 61. (+/-) 6-Phenyl-pyrimidine-4-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 62. (+/-) 6-(2-Fluoro-phenyl)-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 63. (+/-) 2,6-Dimethoxy-N-(4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 64. (+/-) N-(4-Oxo-2-pyrimidin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin 1 0-yI)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide 65. (+/-) 2-Fluoro-N-(4-oxo-2-pyrimidin-4-yI-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-yi)-nicotinamide 66. (+/-) 5-Furan-2-yI-N-(4-oxo-2-pyrimidin-4-yI-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 67. (+/-) 6-Methoxy-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 68. (+/-) Quinoline-3-carboxylic acid (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 69. (+/-) 4-[5-(4-Oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2 a]azepin-1 0-ylcarbamoyl)-pyridin-2-yl]-[1,4]diazepane-1 -carboxylic acid tert-butyl ester 70. (+/-) 5-(2-Methoxy-phenyl)-N-(4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 71. (+/-) 5-(3,4-Dimethoxy-phenyl)-N-(4-oxo-2-pyrimidin-4-yI-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 72. (+/-) 2,6-Dimethoxy-pyrimidine-4-carboxylic acid (4-oxo-2-pyrimidin-4-yi 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yi)-amide 73. (+/-) 5-Bromo-2-methylsulfanyl-pyrimidine-4-carboxylic acid (4-oxo-2- WO 2008/078196 PCT/IB2007/004409 24 pyrimidin-4-yi-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 74. (+/-) [1,5]Naphthyridine-2-carboxylic acid (10-methyl-4-oxo-2-pyrimidin-4-yI 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 O-yl)-amide 75. (+/-) 6-Methoxy-pyridine-2-carboxylic acid (1 0-methyl-4-oxo-2-pyrimidin-4-y 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 O-yl)-amide 76. (+/-) 5-Bromo-2,3-dihydro-benzofuran-7-carboxylic acid (10-methyl-4-oxo-2 pyrimidin-4-yl-4,6,7,8,9, 1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 77. (+/-) N-(10-Ethyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-y)-2-methoxy-nicotinamide 78. (+/-) 2-Methoxy-N-(10-methyl-4-oxo-2-pyridin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 79. (+/-) 2,3-Dihydro-benzofuran-7-carboxylic acid (10-methyl-4-oxo-2-pyridin-4 yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 O-yl)-amide 80. (+/-) 2-Methoxy-N-(10-methyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-y)-nicotinamide 81. (+/-) 2,3-Dihydro-benzofuran-7-carboxylic acid (1 0-methyl-4-oxo-2-pyrimidin-4 yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 82. (+/-) 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (10-methyl-4-oxo-2 pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 83. (+/-) 2,6-Dimethoxy-N-(1 0-methyl-4-oxo-2-pyrimidin-4-yI-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yi)-nicotinamide 84. (+/-) Pyridine-2-carboxylic acid (10-methyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 85. (+/-) 4-Methoxy-pyrid ine-2-carboxylic acid (10-methyl-4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin-10-yl)-amide WO 2008/078196 PCT/IB2007/004409 25 86. (+/-) 3,6-Dimethoxy-pyridazine-4-carboxylic acid (1 0-methyl-4-oxo-2-pyrimidin 4-yi-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 87. (+/-) 6-Chloro-pyridine-2-carboxylic acid (10-methyl-4-oxo-2-pyrimidin-4-yI 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 O-yl)-amide 88. (+/-) 8-Amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid (10 methyl-4-oxo-2-pyrimidin-4-yI-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0 yl)-amide 89. (+/-) 5-Bromo-2-methylsulfanyl-pyrimidine-4-carboxylic acid (10-methyl-4-oxo 2-pyrimidin-4-yi-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 90. (+/-) 6-Bromo-pyridine-2-carboxylic acid (10-methyl-4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 91. (+/-) 3,5-Difluoro-pyridine-2-carboxylic acid (1 0-methyl-4-oxo-2-pyrimidin-4-y 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 92. (+/-) 2,2-Dimethyl-2,3-dihydro-benzofuran-7-carboxylic acid (10-methyl-4-oxo 2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 93. (+/-) 4-Methoxy-pyridine-2-carboxylic acid (10-ethyl-4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 94. (+/-) 5-Chloro-2,3-dihydro-benzofuran-7-carboxylic acid (10-methyl-4-oxo-2 pyrimidin-4-yl-4,6,7,8,9, 1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 95. (+/-) 5-Chloro-2-methylsulfanyl-pyrimidine-4-carboxylic acid (1 0-methyl-4-oxo 2-pyrimidin-4-yi-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 96. (+/-) 8-Amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid (10 ethyl-4-oxo-2-pyrimidin-4-yI-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl) amide 97. (+/-) 3,6-Dimethoxy-pyridazine-4-carboxylic acid (1 0-ethyl-4-oxo-2-pyrimidin-4 yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide WO 2008/078196 PCT/IB2007/004409 26 98. (+/-) 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (10-ethyl-4-oxo-2 pyrimidin-4-yi-4,6,7,8,9, 1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 99. (+/-) N-(10-Ethyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-yl)-2,6-dimethoxy-nicotinamide 100. (+/-) N-(3-Bromo-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-yl)-2-methoxy-nicotinamide 101. (+/-) 6-Chloro-pyridine-2-carboxylic acid (10-ethyl-4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 102. (+) 2,6-Dimethoxy-N-(4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 103. (-) 2,6-Dimethoxy-N-(4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 104. (+) 2-Methoxy-N-(10-methyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10-hexahydro pyrimido[1,2-a]azepin-1 O-yl)-nicotinamide 105. (-) 2,6-Dimethoxy-N-(1 0-methyl-4-oxo-2-pyrimidin-4-yI-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 106. (-) 2-Methoxy-N-(10-methyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 107. (+) 2,6-Dimethoxy-N-(1 0-methyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 108. (-) 5-Bromo-2,3-dihydro-benzofuran-7-carboxylic acid (10-methyl-4-oxo-2 pyrimidin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin-10-yl)-amide 109. (+) 5-Bromo-2,3-dihydro-benzofuran-7-carboxylic acid (10-methyl-4-oxo-2 pyrimidin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin-10-yl)-amide As a further object, the present invention concerns also methods for preparing the pyrimidone compounds represented by the aforementioned formula (1).
WO 2008/078196 PCT/IB2007/004409 27 These compounds can be prepared, for example, according to methods explained below. Preparation method Pyrimidone compounds represented by the aforementioned formula (1), may be prepared according to the method described in the scheme 1. Y R1 R2- L R1 R7 R6 N(1) R7 R6 N R3 N N O R2 z n N O m )o Y m R4 R5 R4 R5 (111) (I) Scheme 1 (In the above scheme the definition of R1, R2, R3, R4, R5, R6, R7, m, n, o, Y and Z are the same as those already described for compound of formula (1)). Following this method, the pyrimidone derivative represented by the above formula (111), wherein R1, R3, R4, R5, R6, R7, m and o are as defined for compound of formula (1), is allowed to react with a base such as triethylamine, sodium carbonate or potassium carbonate in a solvent such as tetrahydrofurane, N-methylpyrrolidone, NN-dimethylacetamide or chloroform at a suitable temperature ranging from 0 to 130*C under ordinary air, then with a compound of formula (11), wherein R2, X, Y and n are as defined for compound of formula (1) and L represents a leaving group preferably chlorine, bromide or mesyl group or hydroxyl group, to obtain the compound of the aforementioned formula (1). Alternatively compounds of formula (1) wherein Y represents two hydrogen atoms may be prepared by reductive amination of a compound of formula (11) wherein Y represents an oxygen atom and L represents a hydrogen atom according to well known methods to one skilled in the art.
WO 2008/078196 PCT/IB2007/004409 28 Compound of formula (II) is commercially available or may be synthesized according to well-known methods to one skilled in the art. Compound of formula (Ill) may be prepared according to the method defined in scheme 2. S R6 NH 2 R1 Ng N PgR N R3 m )o NN R3 R4 R5 m )o 0 (V) R4 R5 RO 0 (IV) (Ill) Scheme 2 (In the above scheme the definition of R1, R3, R4, R5, R6, m and o are the same as already described.) According to this method, the 3-ketoester of formula (IV), wherein R1 and R3 are as defined for compound of formula (1), R is an alkyl group such as for example methyl or ethyl and Pg is a suitable protecting group such as for example a phthalimido group, is allowed to react with a compound of formula (V) wherein R4, R5, R6, m and o are as defined for compound of formula (I). The reaction may be carried out in the presence of a base such as potassium carbonate, in an alcoholic solvent such as methanol, ethanol and the like or without, at a suitable temperature ranging from 25* to 140*C under ordinary air. Additionally compound of formula (Ill) wherein R3 represents a hydrogen atom may be halogenated in order to give compounds of formula (111) wherein R3 is a halogen atom such as a bromine atom or a chlorine atom. The reaction may be carried out in an acidic medium such as acetic acid or propionic acid, in presence of bromosuccinimide or chlorosuccimide, or bromine. In addition, compounds of formula (IV) wherein R3 represents a fluorine atom may be obtained by analogy to the method described in Tetrahedron Letters, Vol.30, No. 45, pp 6113-6116, 1989.
WO 2008/078196 PCT/IB2007/004409 29 In addition, compounds of formula (IV) wherein R3 represents a hydrogen atom may be obtained by analogy to the method described in patent DE 2705582. As a further object, the present invention concerns also the compounds of formula (III) as intermediates of compounds of formula (I). Compound of formula (IV) is commercially available or may be synthesized according to well-known methods to one skilled in the art. For example compounds of formula (IV), wherein R1 represents a pyridine ring or a pyrimidine ring, optionally substituted by a C1_6 alkyl group, C 1
.
6 alkoxy group or a halogen atom, can be prepared by reacting respectively an isonicotinic acid or a pyrimidine-carboxylic acid, optionally substituted by a C 1
.
6 alkyl group, C 1
.
6 alkoxy group or a halogen, with the corresponding malonic acid monoester. The reaction can be carried out using methods well known to one skilled in the art, such as for example in presence of a coupling agent such as 1,1'-carbonylbis-1H-imidazole in a solvent such as tetrahydrofuran at a temperature ranging from 20 to 70"C. Compound of formula (V) may be synthesized according to well-known methods of one skilled in the art. For example compound of formula (V), wherein m, o, R4, R5 and R6 are as defined for compound of formula (I) and Pg is a suitable protecting group such as for example a phthalimido group, may be prepared according to the method defined in scheme 3, starting from compound of formula (VI). The conditions which may be used are given in the chemical examples. Pg 0 Pg OR Pg NH 2 R6 I1R6 NH3 N R N N R NNN m )o m( )o m( )o R4 R5 R4 R5 R4 R5 (VI) (VII) (V) Scheme 3 WO 2008/078196 PCT/IB2007/004409 30 Compound of formula (VI) may be synthesized by analogy to the methods described in Heterocycles (1996), 42 (2), 537-42, Enantiomer (2001), 6 (5), 275 279 and Synthesis (1991), (5), 417-20. Compound of formula (VII) and formula (V) may be synthesized according to the method described in W09614844. Alternatively compounds of formula (Ill) wherein R1, R3, R4, R5, R7, m and o are as defined for compound of formula (I) and R6 represents a hydrogen atom, a C1.
6 alkyl group optionally substituted by a halogen atom or a cycloalkyl group, may be prepared according to the method defined in scheme 4, starting from compound of formula (IV).
NH
2 N R1 R1 m )o R3 R3 RI N N R3 R4 R5 I R6 0 (VI) N 0 R6-L N 0 RO O )o m )o R4 R5 R4 R5 (IV) (VII) (Vill) R6 = H { R1 R3 R7 N I R6 HN N 0 m )o R4 R5 (111) Scheme 4 According to this method, the 3-ketoester of formula (IV), wherein R1 and R3 are WO 2008/078196 PCT/IB2007/004409 31 as defined for compound of formula (1), R is an alkyl group such as for example methyl or ethyl is allowed to react with a compound of formula (VI) wherein R4, R5, m and o are as defined for compound of formula (1) to afford the compound of formula (VII). The reaction may be carried out in the presence of a base such as potassium carbonate, in an alcoholic solvent such as methanol, ethanol and the like or without, at a suitable temperature ranging from 250 to 1400C under ordinary air. The compound of formula (VII) wherein R1, R3, R4, R5, m and o are as defined for compound of formula (1) can be deprotonated with strong base (such as lithium bis(trimethylsilyl)amide or lithium diisopropyl amide) and the resultant anion reacted with suitable electrophiles R6-L wherein R6 represents a C1.6 alkyl group optionally substituted by a halogen atom or a cycloalkyl group and L represents a leaving group such as bromine, iodine or mesyl group to afford the compound of formula (VIII). The compound of formula (VIll) wherein R1, R3, R4, R5, m and o are as defined for the compound of formula (1) and R6 represents a C 1
.
6 alkyl group optionally substituted by a halogen atom or a cycloalkyl group, can be deprotonated with strong base (such as lithium bis(trimethylsilyl)amide or lithium diisopropyl amide) followed by addition of an electrophilic nitrogen source such as trisyl azide to afford compound of formula (Ill) wherein R1, R3, R4, R5, R7, m and o are as defined for compound of formula (I) and R6 represents a C1-6 alkyl group optionally substituted by a halogen atom or a cycloalkyl group. The compound of formula (VII) wherein R1, R3, R4, R5, m and o are as defined for the compound of formula (1) can be deprotonated with strong base (such as lithium bis(trimethylsilyl)amide or lithium diisopropyl amide) followed by addition of an electrophilic nitrogen source such as trisyl azide to afford compound of formula (111) wherein R1, R3, R4, R5, R7, m and o are as defined for compound of formula (I) and R6 represents a hydrogen. The conditions which may be used are given in the chemical examples. Compound of formula (VI) may be synthesized according to the methods described in W096/14844 and Journal of Medicinal Chemistry (1998), 41(9), 1361-1366.
WO 2008/078196 PCT/IB2007/004409 32 In the above reactions protection or deprotection of a functional. group may sometimes be necessary. A suitable protecting group Pg can be chosen depending on the type of the functional group, and a method described in the literature may be applied. Examples of protecting groups, of protection and deprotection methods are given for example in Protective groups in Organic Synthesis Greene et al., (John Wiley & Sons, Inc., New York) 4 th Ed. 2007. The compounds of the present invention have inhibitory activity against GSK3p. Accordingly, the compounds of the present invention are useful as an active ingredient for the preparation of a medicament, which enables preventive and/or therapeutic treatment of a disease caused by abnormal GSK3p activity and more particularly of neurodegenerative diseases such as Alzheimer's disease. In addition, the compounds of the present invention are also useful as an active ingredient for the preparation of a medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Parkinson's disease, tauopathies (e.g. frontotemporoparietal dementia, corticobasal degeneration, Pick's disease, progressive supranuclear palsy) and other dementia including vascular dementia; acute stroke and others traumatic injuries; cerebrovascular accidents (e.g. age related macular degeneration); brain and spinal cord trauma; peripheral neuropathies; retinopathies and glaucoma; and other diseases such as non-insulin dependent diabetes (such as diabetes type II ) and obesity; manic depressive illness; schizophrenia; alopecia; cancers such as breast cancer, non small cell lung carcinoma, thyroid cancer, T or B-cell leukemia and several virus induced tumors. The present invention further relates to a method for treating neurodegenerative diseases caused by abnormal activity of GSK3P and of the aforementioned diseases which comprises administering to a mammalian organism in need thereof an effective amount of a compound of the formula (1). As the active ingredient of the medicament of the present invention, a substance may be used which is selected from the group consisting of the compound represented by the aforementioned formula (I) and pharmacologically acceptable salts thereof, and solvates thereof and hydrates thereof. The substance, per se, may be administered as the medicament of the present invention, however, it is desirable to administer the medicament in a form of a pharmaceutical composition which comprises the aforementioned substance as an active ingredient and one or more pharmaceutical additives. As the active WO 2008/078196 PCT/IB2007/004409 33 ingredient of the medicament of the present invention, two or more of the aforementioned substances may be used in combination. The above pharmaceutical composition may be supplemented with an active ingredient of another medicament for the treatment of the above mentioned diseases. The type of pharmaceutical composition is not particularly limited, and the composition may be provided as any formulation for oral or parenteral administration. For example, the pharmaceutical composition may be formulated, for example, in the form of pharmaceutical compositions for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions, solutions and the like, or in the form of pharmaceutical compositions for parenteral administrations such as injections for intravenous, intramuscular, or subcutaneous administration, drip infusions, transdermal preparations, transmucosal preparations, nasal drops, inhalants, suppositories and the like. Injections or drip infusions may be prepared as powdery preparations such as in the form of lyophilized preparations, and may be used by dissolving just before use in an appropriate aqueous medium such as physiological saline. Sustained-release preparations such as those coated with a polymer may be directly administered intracerebrally. Types of pharmaceutical additives used for the manufacture of the pharmaceutical composition, content ratios of the pharmaceutical additives relative to the active ingredient, and methods for preparing the pharmaceutical composition may be appropriately chosen by those skilled in the art. Inorganic or organic substances, or solid or liquid substances may be used as pharmaceutical additives. Generally, the pharmaceutical additives may be incorporated in a ratio ranging from 1% by weight to 90% by weight based on the weight of an active ingredient. Examples of excipients used for the preparation of solid pharmaceutical compositions include, for example, lactose, sucrose, starch, talc, cellulose, dextrin, kaolin, calcium carbonate and the like. For the preparation of liquid compositions for oral administration, a conventional inert diluent such as water or a vegetable oil may be used. The liquid composition may contain, in addition to the inert diluent,. auxiliaries such as moistening agents, suspension aids, sweeteners, aromatics, colorants, and preservatives. The liquid composition may be filled in capsules made of an absorbable material such as gelatin. Examples of solvents or suspension mediums used for the preparation of compositions for parenteral administration, e.g. injections, suppositories, include water, propylene WO 2008/078196 PCT/IB2007/004409 34 glycol, polyethylene glycol, benzyl alcohol, ethyl oleate, lecithin and the like. Examples of base materials used for suppositories include, for example, cacao butter, emulsified cacao butter, lauric lipid, witepsol. The dose and frequency of administration of the medicament of the present invention are not particularly limited, and they may be appropriately chosen depending on conditions such as a purpose of preventive and/or therapeutic treatment, a type of a disease, the body weight or age of a patient, severity of a disease and the like. Generally, a daily dose for oral administration to an adult may be 0.01 to 1,000 mg (the weight of an active ingredient), and the dose may be administered once a day or several times a day as divided portions, or once in several days. When the medicament is used as an injection, administrations may preferably be performed continuously or intermittently in a daily dose of 0.001 to 100 mg (the weight of an active ingredient) to an adult.
WO 2008/078196 PCT/IB2007/004409 35 Chemical Examples Example 1 (Compound No. 2 of table 1) (+/-)1 -Methyl-N-(4-oxo-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin 9-yl)-1 H-1,2,3-benzotriazole-5-carboxamide 1.1 (+/-)2-(2-Methoxy-3,4,5,6-tetrahydropyridin-3-yl)-1H-isoindole-1,3(2H)-dione To a solution of 13.474g (91.1 mmol) of trimethyloxonium tetrafluoroborate in 294 mL of anhydrous dichloromethane was added 22.25g (91.1 mmol) of (+/-)-3 phtalimidopiperidin-2-one (Heterocycles (1996), 42(2), 537-42, Enantiomer (2001), 6(5), 275-279, Synthesis (1991), (5), 417-20) and the resulting mixture was stirred at room temperature for 12h. The mixture was hydrolyzed with a saturated aqueous solution of sodium hydrogen carbonate, extracted with dichloromethane, dried over sodium sulfate and the solvent was evaporated to afford 23.22g (99%) of pure product as a yellow oil. The compound was used as such in the next step. RMN 1 H (CDCl 3 ; 200 MHz) 6 (ppm) : 7.66-7.92 (m, 4H) ; 4.69-4.87 (m, 1H) ; 3.60-3.74 (m, 2H) ; 3.56 (s, 3H); 1.62-2.40 (m, 4H). 1.2 (+/-) 2-(2-Amino-3,4,5,6-tetrahydropyridin-3-yl)-1H-isoindole-1,3(2H)-dione hydrochloride (1:1). To a solution of 23.224g (89.92 mMol) of (+/-)2-(2-methoxy-3,4,5,6 tetrahydropyridin-3-yl)-1 H-isoindole-1,3(2H)-dione dissolved in 409 mL of methanol was added at room temperature 4.81g (89.92 mmol) of ammonium chloride. The resulting mixture was stirred under reflux for 12h. The cooled solution was evaporated to remove solvent. The residue was triturated with diethyl ether and filtered to afford 23.8g (95%) of the pure product as a white powder. Mp: 242-244*C. RMN 1 H (DMSO-d 6 ; 200 MHz) 6 (ppm) : 8.92 (br s, 2H) ; 7.85-8.02 (m, 4H) ; 5.28 (t, 1H) ; 3.12-3.58 (m, 2H) 1.78-2.15 (m, 4H). 1.3 (+/-) 2-(4-Oxo-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyriimidin-9-yl) 1 H-isoindole-1,3(2H)-dione WO 2008/078196 PCT/IB2007/004409 36 To a suspension of 9.166g (32.77 mmol) of (+/-) 2-(2-Amino-3,4,5,6 tetrahydropyridin-3-yl)-1H-isoindole-1,3(2H)-dione hydrochloride (1:1) in 50 mL of toluene was added sodium methanolate (freshly prepared from 0.754g (32.77 mmol) of sodium in 10 mL of methanol and the reaction mixture was stirred at room temperature for 1 h. The mixture was evaporated to dryness, dissolved in 50 mL of toluene and 4.87g (25.21 mmol) of ethyl 3-(pyridin-4-yl)-3-oxopropionate was added. The resulting solution was stirred under reflux for 12h. The cooled solution was evaporated to remove solvent. The mixture was dissolved in dichloromethane, washed with a saturated aqueous solution of ammonium chloride, saturated aqueous sodium chloride, dried over sodium sulfate and evaporated to dryness. The residue was chromatographed on silica gel eluting with a mixture of dichloromethane/methanol/aqueous ammonia solution (29%) in the proportions 97/3/0.3 led to afford 3.2g (34%) of the desired compound as a white powder. Mp: 211-213*C. RMN 1 H (DMSO-d 6 ; 200 MHz) 6 (ppm) : 8.50 (d, 2H) ; 7.78-8.09 (m, 4H) ; 7.60 (d, 2H) ; 7.08 (s, 1H) ; 5.39-5.60 (m, 1H) ; 4.06-4.28 (m, 1H) ; 3.65-3.3.88 (m, 1H) ; 2.08-2.55 (m, 4H). 1.4 (+/-) 9-Amino-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyriimidin-4-one To a solution of 3.2g (8.59 mmol) of (+/-) 2-(4-oxo-2-pyridin-4-yl-6,7,8,9 tetrahyd ro-4H-pyrido[1,2-a]pyrimidin-9-yl)-1 H-isoindole-1,3(2H)-dione dissolved in 24 mL of ethanol was added 2.09 mL (43 mmol) of hydrazine hydrate and the resulting mixture was stirred under reflux for 2h. The mixture was filtered and the solid obtained was triturated with dichloromethane for 24h, filtered, and the resulting filtrates were evaporated to dryness. The resulting residue was purified on silica gel eluting with a mixture of dichloromethane/methanol in the proportions 98/2 to 96/4 to give 1.37g (66%) of the desired compound as a brown powder. Mp: 144-146"C. RMN 1 H (CDCl 3 ; 200 MHz) 6 (ppm) : 8.77 (d, 2H) ; 7.85 (d, 2H) ; 6.89 (s, 1H) ; 3.91-4.26 (m, 3H) ; 1.61-2.48 (m, 6H). 1.5 (+1-) 1-Methyl-N-(4-oxo-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1 ,2 a]pyrimidin-9-yl)-1 H-1,2,3-benzotriazole-5-carboxamide To a solution of 0.050g (0.21 mmol) of (+/-) 9-amino-2-pyridin-4-yl-6,7,8,9- WO 2008/078196 PCT/IB2007/004409 37 tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one dissolved in 2.2 mL of tetrahydrofuran was added 30 pl (0.25 mmol) of triethylamine and 0.0484g (0.25 mmol) of 1 methyl-1H-1,2,3-benzotriazole-5-carbonyl chloride. The resulting mixture was stirred at room temperature for 16h. Water was added and the mixture extracted with ethyl acetate. The extracts were washed with a saturated aqueous solution of ammonium chloride, dried and evaporated. The residue was purified by silica gel chromatography, eluting with dichloromethane/methanol/ammonia in the proportions 95/5/0.5 to give 0.041g of pure product obtained in the form of free base. Mp: 267-269*C. RMN 1 H (DMSO-d 6 ; 200 MHz) 6 (ppm) : 9.15 (d, 1H) ; 8.55 (m, 3H) ; 8.20-7.80 (m, 4H) ; 7.10 (s, 1H) ; 5.20 (m, 1H) ; 4.45 (s, 3H) ; 3.90 (m, 2H) ; 2.20-1.80 (m, 4H). Example 2 (compound No.4 of table 1) (+/-) N-(4-Oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl) 2,3-dihydro-1 -benzofuran-7-carboxamide 2.1 (+/-) 2-(4-Oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9 yl)-l H-isoindole-1,3(2H)-dione By analogy with the method described in example 1 (step 1.3), using ethyl 3-(4 pyrimidinyl)-3-oxopropionate (prepared by analogy to the method described in patent DE 2705582) in place of ethyl 3-(pyridin-4-yl)-3-oxopropionate, the compound was obtained as a white powder. Mp. : 279.9-280.9"C. RMN 1 H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.21 (s, 1H) ; 8.75 (d, 1H) ; 8.01-7.81 (m, 4H) ; 7.52 (d, 1H) ; 7.19 (s, 1H) ; 5.58-5.40 (m, 1H) ; 4.26-4.09 (m, 1H) ; 3.89-3.68 (m, 1H) ; 2.48-2.02 (m, 4H.). 2.2 (+/-) 9-Amino-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4 one By analogy with the method described in example 1 (step 1.4), using (+/-) 2-(4 oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahyd ro-4H-pyrido[1,2-a]pyrimid in-9-yl)-1 H isoindole-1,3(2H)-dione in place of (+/-) 2-(4-oxo-2-pyridin-4-yl-6,7,8,9-tetrahydro 4H-pyrido[1,2-a]pyrimidin-9-yl)-1 H-isoindole-1,3(2H)-dione, the compound was WO 2008/078196 PCT/IB2007/004409 38 obtained as a brown powder. Mp. : 111-113*C. RMN 'H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.29 (s, 1H) ; 8.99 (d, 1H) ; 8.43 (d, 1H) ; 7.18 (s, 1H) ; 4.02-3.75(m, 3H) ; 2.25 (br s ; 2H) ; 2.23-1.75 (m, 3H) ; 1.74-1.48 (m, 1H). 2.3 (+/-) N-(4-Oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-ajpyrimidin-9 yl)-2,3-dihydro-1 -benzofuran-7-carboxamide By analogy with the method described in example 1 (step 1.5), using (+/-) 9 amino-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one in place of (+/-) 9-amino-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one, the compound was obtained as a white powder. Mp: 294-296*C. RMN 1 H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.30 (s, 1H) ; 9.10 (d, 1H) ; 8.90 (d, 1H) ; 8.25 (d, 1H) 7.55 (d, 1H) 7.40 (d, 1H) ; 7.25 (s, 1H) ; 6.90 (t, 1H) ; 5.10 (m, 1H) ; 4.75 (m, 2H) ; 4.20 (m, 1H) ; 3.75 (m, 1H) ; 3.25 (m, 2H) ; 2.55(m, 1H) ; 2.10-1.80 (m, 2H) ; 1.60 (m, 1H). Example 3 (Compound No. 14 of table 3) (+) 2-Methoxy-N-(4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2 a]azepin-1 0-yl)-nicotinamide 3.1 2-(7-methoxy-3,4,5,6-tetrahydro-2H-azepin-6-yl)-1 H-isoindole-1,3(2H)-dione By analogy with the method described in example 1 (step 1.1), using X-amino-E caprolactam monohydrochloride (commercially available) in place of 3 phthalimidopiperidin-2-one, the compound was obtained as a yellow oil. RMN 1 H ((CDCl3 ; 200MHz) 6 (ppm) : 7.92-7.66 (m, 4H) ; 5.10 (d, 1H) ; 3.90-3.70 (m, 1H) ; 3.50 (s, 3H) ; 3.40 3.30 (m, 1H) ; 2.70-2.50 (m, 1H) ; 2.10 (m, 1H) 1.90-1.20 (m, 4H). 3.2 2-(2-iminoazepan-3-yl)-1H-isoindole-1,3(2H)-dione hydrochloride (1:1) By analogy with the method described in example 1 (step 1.2), using 2-(7 methoxy-3,4,5,6-tetrahydro-2H-azepin-6-yl)-1H-isoindole-1,3(2H)-dione in place of WO 2008/078196 PCT/IB2007/004409 39 2-(2-methoxy-3,4,5,6-tetrahydropyridin-3-y)-1 H-isoindole-1,3(2H)-dione, the compound was obtained as a white powder. Mp. : 120-122'C. RMN 1 H (CDCl3; 200MHz) 6 (ppm) : 9.40 (br s, 1H) ; 8.70 (br s, 1H) ; 8.20-7.60 (m, 4H) ; 5.28 (br t, 1H) 3.90-3.40 (m, 3H) ; 2.30-1.30 (m, 5H). 3.3 (+/-) 2-(4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepin 1 0-yl)-1 H-isoindole-1,3(2H)-dione By analogy with the method described in example 1 (step 1.3), using ethyl 3-(4 pyrimidinyl)-3-oxopropionate (prepared by analogy to the method described in patent DE 2705582) in place of ethyl 3-(pyridin-4-yl)-3-oxopropionate and using 2 (2-iminoazepan-3-y)-1 H-isoindole-1,3(2H)-dione hydrochloride (1:1), the compound was obtained as a white powder. Mp. :250-2520C. RMN 'H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.30 (s, 1H) ; 8.60 (d, 1H) ; 8.00 (m, 3H) ; 7.40 (m, 1H) ; 7.20 (m, 2H) 4.70 (d, 2H) ; 3.50 (m, 2H) ; 2.00-1.50 (m, 4H) ; 1.30 (m, 1H). 3.4 (+/-) 1 0-amino-2-pyrimidin-4-yl-7,8,9,1 0-tetrahydropyrimido[1,2-a]azepin 4(6H)-one By analogy with the method described in example 1 (step 1.4), using (+/-) 2-(4 oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydropyrimido[1,2-a]azepin-1 0-yl)-1 H isoindole-1,3(2H)-dione in place of (+/-) 2-(4-oxo-2-pyridin-4-yl-6,7,8,9-tetrahydro 4H-pyrido[1,2-a]pyrimidin-9-yl)-1 H-isoindole-1,3(2H)-dione, the compound was obtained as a brown powder. Mp. : 157-159 *C. RMN 1 H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.30 (s, 1H) ; 9.00 (d, 1H) ; 8.40 (d, 1H) ; 7.20 (s, 1H) ; 5.00-4.80 ( m, 1H) ; 4.25 (d, 1H) ; 3.80-3.60 (dd, 1H) ; 2.00-1.20 (m, 6H). 3.5 (+) 10-amino-2-pyrimidin-4-yl-7,8,9,10-tetrahydropyrimido[1,2-a]azepin-4(6H) one 20g (77.73 mmol) of (+/-) 10-amino-2-pyrimidin-4-yl-7,8,9,10 tetrahydropyrimido[1,2-a]azepin-4(6H)-one was separated by chirale preparative WO 2008/078196 PCT/IB2007/004409 40 HPLC (Daicel CHIRALPACK AD 20pm 50x220) eluting with ethanol to give 9.17g of pure product obtained in the form of free base. tR: 12.0 min. Mp. : 118 *C. [a]D 20 = + 59.970 (c=0.691, DMSO). RMN 1 H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.30 (s, 1H) ; 9.0 (d, 1H) ; 8.4 (d, 1H) ; 7.2 (s, 1H) ; 5.0-4.8 (in, 1H) 4.25 (d, 1H) ; 3.8-3.6 (dd, 1H) ; 2.0-1.2 (m, 6H). 3.6 (-) 10-amino-2-pyrimidin-4-yl-7,8,9,10-tetrahydropyrimido[1,2-a]azepin-4(6H) one 20g (77.73 mmol) of (+/-) 10-amino-2-pyrimidin-4-yl-7,8,9,10 tetrahydropyrimido[1,2-a]azepin-4(6H)-one was separated by chirale preparative HPLC (Daicel CHIRALPACK AD 20pm 50x220) eluting with ethanol to give 9.05g of pure product obtained in the form of free base. tR 41.0 min. Mp. : 117.8 *C. [aD20 = - 59.760 (c=0.619, DMSO). RMN 1 H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.30 (s, 1H) ; 9.00 (d, 1H) ; 8.40 (d, 1H) ; 7.20 (s, 1H) ; 5.00-4.80 ( m, 1H) ; 4.25 (d, 1H) ; 3.80-3.60 (dd, 1H) ; 2.00-1.20 (m, 6H). 3.7 (+) 2-Methoxy-N-(4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-yl)-nicotinamide To a solution of 3.50g (13.60 mmol) of (+) 10-amino-2-pyrimidin-4-yl-7,8,9,10 tetrahydropyrimido[1,2-a]azepin-4(6H)-one dissolved in 113 mL of dimethylformamide were added at 0*C 2.083g (13.60 mmol) of 2-methoxy nicotinic acid, 2.86g (13.60 mmol) of diethylcyanophosphonate and 1.9 mL (13.60 mmol) of triethylamine. The resulting mixture was stirred at room temperature for 16h. Water and ethyl acetate were added and the mixture stirred for 8 h. The precipitate was filtered and refluxed with isopropanol. The residue was triturated with diisopropylether to give 3.745g (70%) of pure product obtained in the form of free base. Mp : 214-216*C. [a]D 20 = +5.04* (c=0.963, DMSO). RMN 1 H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.40 (d, 1H) ; 9.30 (s, 1H) ; 9.10 (d, 1H) ; 8.40-8.20 (m, 3H) ; 7.30-7.15 WO 2008/078196 PCT/IB2007/004409 41 (m, 2H) ; 5.40 (dd, 1H) ; 5.00 (dd, 1H) ; 4.10 (s, 3H) ; 3.70 (dd, 1H) ; 2.25-2.10 (m, 1 H) ; 2.09-1.80 (m, 3H) ; 1.80-1.60 (m, 1 H) ; 1.40-1.20 (m, 1 H). Example 4 (Compound No. 15 of table 3) (-) 2-Methoxy-N-(4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2 a]azepin-1 0-yl)-nicotinamide By analogy with the method described in example 3 (step 3.7), using (-) 10-amino 2-pyrimidin-4-yl-7,8,9,10-tetrahydropyrimido[1,2-a]azepin-4(6H)-one (step 3.6) in place of (+) 10-amino-2-pyrimidin-4-yl-7,8,9,10-tetrahydropyrimido[1,2-a]azepin 4(6H)-one, the compound, 3.22g (60%), was obtained as a white powder. Mp: 212-214'C. [ca]D 20 = -6.41* (c=0.751, DMSO). RMN 'H (DMSO-d ; 200MHz) 6 (ppm) : 6 (ppm) 9.40 (d, 1H) ; 9.30 (s, 1H) ; 9.10 (d, 1H) ; 8.40-8.20 (m, 3H) 7.30-7.15 (m, 2H) ; 5.40 (dd, 1H) ; 5.00 (dd, 1H) ; 4.10 (s, 3H) ; 3.70 (dd, 1H) 2.25-2.10 (m, 1H) ; 2.09-1.80 (m, 3H) ; 1.80-1.60 (m, 1H) ; 1.40-1.20 (m, 1H). Example 5 (Compound No. 2 of table 2) (+/-) 1-Methyl-1H-benzotriazole-5-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6,7,8 tetrahyd ro-pyrrolo[1,2-a]pyrimidin-8-yl)-amide 5.1 2-(2-Methoxy-4,5-dihydro-3H-pyrrol-3-yl)-isoindole-1,3-dione By analogy with the method described in example 1 (step 1.1), using 2-(2-Oxo pyrrolidin-3-yl)-isoindole-1,3-dione (prepared by analogy to the method described in (Heterocycles (1996), 42(2), 537-42, Enantiomer (2001), 6(5), 275-279, Synthesis (1991), (5), 417-20)) in place of 3-phtalimidopiperidin-2-one, the compound was obtained as a white powder. Mp. : 139-141*C. RMN 'H (DMSO-d 6 ; 200MHz) 6 (ppm) : 7.95-7.70 (m, 4H) ; 5.20 (dd, 1H) ; 3.90-3.50 (m, 5H) ; 2.50-2.10 (m, 2H). 5.22-(2-Amino-4,5-dihydro-3H-pyrrol-3-yl)-isoindole-1,3-dione hydrochloride (1 : 1) By analogy with the method described in example 1 (step 1.2), using 2-(2 methoxy-4,5-dihydro-3H-pyrrol-3-yl)-isoindole-1,3-dione in place of 2-(2-methoxy- WO 2008/078196 PCT/IB2007/004409 42 3,4,5,6-tetrahyd ropyridin-3-yl)-1 H-isoindole- 1, 3(2H)-dione, the compound was obtained as a white powder. Mp. : 121-123*C. RMN 1 H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.25-8.80 (br s, 3H) ; 7.95-7.70 (m, 4H) ; 5.65 (dd, 1H) ; 3.90-3.50 (m, 2H) ; 2.50-2.20 (m, 2H). 5.3 (+/-) 2-(4-Oxo-2-pyridin-4-yl-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidin-8-yl) isoindole-1,3-dione By analogy with the method described in example 1 (step 1.3), using ethyl 3-(4 pyridinyl)-3-oxopropionate (prepared by analogy to the method described in patent DE 2705582) and using 2-(2-amino-4,5-dihydro-3H-pyrrol-3-yl)-isoindole 1,3-dione, the compound was obtained as a white powder. Mp. : 224-226*C. RMN 1 H (DMSO-d 6 ; 200MHz) 6 (ppm): 8.60 (d, 2H) ; 8.00-7.70 (m, 6H) ; 7.05 (s, 1H) ; 5.90 (t, 1H) ; 4.40-4.20 (m, 1H) ; 3.80-4.10 (m, 1H) ; 2.70-2.40 (m, 2H). 5.4 (+/-) 8-Amino-2-pyridin-4-yl-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidin-4-one By analogy with the method described in example 1 (step 1.4), using 2-(4-oxo-2 pyridin-4-yl-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidin-8-yI)-isoindole-1,3-dione in place of (+/-) 2-(4-oxo-2-pyridin-4-yl-6,7,8,9-tetrahyd ro-4H-pyrido[1,2-a]pyrimidin 9-yl)-1 H-isoindole-1,3(2H)-dione, the compound was obtained as a brown powder. Mp. : 187-189*C. RMN 1 H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.40 (s, 1H) ; 9.10 (d, 1H) ; 8.40 (d, 1H) ; 7.30 (s, 1H) ; 4.30(dd, 1H) 4.20-3.70 (m, 2H) ; 2.00-1.70 (m, 2H). 5.5 (+/-) 1-Methyl-1 H-benzotriazole-5-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6,7,8 tetrahydro-pyrrolo[1,2-alpyrimidin-8-yl)-amide By analogy with the method described in example 1 (step 1.5), using (+/-) 8 amino-2-pyrimidin-4-yl-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidin-4-one in place of (+/-) 9-amino-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one, the compound was obtained as a white powder. Mp: 393-395*C.
WO 2008/078196 PCT/IB2007/004409 43 RMN 'H (DMSO-d 6 ; 200MHz) 6 (ppm): 9.35 (d, 1H) ; 8.70-8.50 (im, 3H); 8.15-8.00 (m, 1H) ; 7.95-7.85 (m, 3H) 7.05 (s, 1H) ; 5.50 (dd, 1H) ; 4.35 (s, 3H) ; 4.30-4.10 (m, 1H) ; 4.05-3.85 (m, 1H) ;2.75-2.50 (m, 1H) ; 2.35-2.10 (m, 1H). Example 6 (Compound No. 34 of table 1) (+/-) 2-Methoxy-N-(9-methyl-4-oxo-2-pyrim id i n-4-yl-6,7,8,9-tetrahydro-4 H pyrido[1,2-a]pyrimidin-9-yl)-nicotinamide 6.1 (+/-) 2-(2-methoxy-3-methyl-3,4,5,6-tetrahydropyridin-3-yl)-1 H-isoindole 1,3(2H)-dione By analogy with the method described in example 1 (step 1.1), using 2-(3-methyl 2-oxopiperidin-3-yi)-1H-isoindole-1,3(2H)-dione (prepared by analogy to the method described in Liebigs Annalen der Chemie (1987), (7), 647-8. Archiv der Pharmazie (Weinheim, Germany) (1989), 322(8), 499-505, (Heterocycles (1996), 42(2), 537-42, Enantiomer (2001), 6(5), 275-279, Synthesis (1991), (5), 417-20)) in place of 3-phtalimidopiperidin-2-one, the compound was obtained as a yellow oil. RMN 'H (DMSO-d 6 ; 200MHz) 6 (ppm) : 7.80 (m, 4H) ; 3.40 (m, 4H) ; 2.30-2.10 (m, 1H) ; 1.90-1.70 (m, 5H) 1.65 1.40 (m, 2H). 6.2 (+/-) 2-(2-amino-3-methyl-3,4,5,6-tetrahydropyridin-3-yl)-1 H-isoindole 1,3(2H)-dione hydrochloride (1:1) By analogy with the method described in example 1 (step 1.2), using (+/-) 2-(2 methoxy-3-methyl-3,4,5,6-tetrahydropyridin-3-yl)-1 H-isoindole-1,3(2H)-dione in place of 2-(2-methoxy-3,4,5,6-tetrahydropyridin-3-y1)-1 H-isoindole-1,3(2 H)-dione, the compound was obtained as a white powder. Mp. : 165-167*C. RMN 1 H (DMSO-d 6 ; 200MHz) 6 (ppm) : 7.70-7.10 (m, 4H) ; 3.20-3.00 (m, 2H) ; 2.40-2.20 (m, 1H) ; 1.80-1.60 (m, 3H), 1.20 (s, 3H). 6.3 (+/-) 2-(1 -methyl-5-oxo-7-pyrimidin-4-yl-1,2,3,4,4a,5-hexahydronaphthalen-1 - WO 2008/078196 PCT/IB2007/004409 44 yl)-1 H-isoindole-1,3(21H)-dione By analogy with the method described in example 1 (step 1.3), using ethyl 3-(4 pyrimidinyl)-3-oxopropionate (prepared by analogy to the method described in patent DE 2705582) in place of ethyl 3-(pyridin-4-yl)-3-oxopropionate and using 2 (2-amino-3-methyl-3,4,5,6-tetrahydropyridin-3-yl)-1 H-isoindole-1,3(2H)-dione hydrochloride (1:1) the compound was obtained as a white powder. Mp. : 184-186 0 C. RMN 'H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.25 (s, 1H) ; 8.80 (d, 1H) ; 8.00 (d, 2H) ; 7.80 (m, 4H) ; 7.20 (s, 1H) 4.30-4.10 (dt, 1H) ; 3.80 -3.60(m, 1H) ; 2.50 (m, 1H) ; 2.15 (s, 3H) , 2.10-1.80 (m, 2H). 6.4 (+/-) 5-amino-5-methyl-3-pyrimidin-4-yl-6,7,8,8a-tetrahydronaphthalen-1 (5H) one By analogy with the method described in example 1 (step 1.4), using (+/-) 2-(1 methyl-5-oxo-7-pyrimidin-4-yl-1,2,3,4,4a, 5-hexahydronaphthalen-1 -yl)-1 H isoindole-1,3(2H)-dione in place of (+/-) 2-(4-oxo-2-pyridin-4-yl-6,7,8,9-tetrahydro 4H-pyrido[1,2-a]pyrimidin-9-yl)-1H-isoindole-1,3(2H)-dione, the compound was obtained as a brown powder. Mp. : 138-140*C. RMN 'H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.25 (s, 1H) ; 9.00 (d, 1H) ; 8.40 (d, 2H) ; 7.15 (s, 1H) ; 4.00-3.70 (m, 2H) ; 2.30 (br s, 2H) ; 2.10-1.70 (m, 3H) ; 1.45 (s, 3H). 6.5 (+/-) 2-Methoxy-N-(9-methyl-4-oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H pyrido[1,2-a]pyrimidin-9-yl)-nicotinamide By analogy with the method described in example 1 (step 1.5), using (+/-) 5 amino-5-methyl-3-pyrimidin-4-yl-6,7,8,8a-tetrahydronaphthalen-1(5H)-one in place of (+/-) 9-amino-2-pyridin-4-yI-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one, the compound was obtained as a white powder. Mp: 193-195*C. RMN 1H (DMSO-d"; 200MHz) 6 (ppm) : 9.25 (s, 1H) ; 8.80 (s, 1H) ; 8.75 (d, 1H) ; 8.40-8.25 (m, 2H) ; 8.10 (dd, 1H) ; 7.50 (s, 1H) ; 7.15 (t, 1H) ; 4.55 (dd, 1H) ; 4.15 (s, 3H) ; 3.90-3.70 (m, 1H); 2.80-2.60 (m, 1H) 2.40-2.15 (m, 2H) 2.14-1.90 (m, 1H) ; 1.85 (s, 3H).
WO 2008/078196 PCT/IB2007/004409 45 Example 7 (Compound No. 58 of table 1) (+) 6-(2-Fluoro-phenyl)-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl-6,7,8,9 tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 0.115g (0.26 mmol) of (+/-) 6-(2-Fluoro-phenyl)-pyridine-2-carboxylic acid (4-oxo 2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide (compound 46 of table) was separated by chirale preparative HPLC (Daicel CHIRALCELL OD-H 20pm 50x220) eluting with ethanol to give 0.046g of pure product obtained in the form of free base. tR: 12.7 min. Mp. : 200-202"C. [OC20 = + 94.25" (c=0.257, DMSO). RMN 'H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.45 (d, 1H) ; 9.35 (s, 1H) ; 8.6 (d, 1H) ; 8.20-7.90 (m, 5H) ; 7.60-7.10 (m, 4H); 5.30-5.10 ( m, 1H) ; 4.00 (t, 2H) ; 2.40-2.20 (m, 1H) ; 2.10-1.80 (m, 3H). Example 8 (Compound No. 59 of table 1) (-) 6-(2-Fluoro-phenyl)-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl-6,7,8,9 tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 0.115g (0.26 mmol) of (+/-) 6-(2-Fluoro-phenyl)-pyridine-2-carboxylic acid (4-oxo 2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide (compound 46 of table) was separated by chirale preparative HPLC (Daicel CHIRALCELL OD-H 20pm 50x220) eluting with ethanol to give 0.042g of pure product obtained in the form of free base. tR: 10.
9 min. Mp. : 199-200*C. [a]D 20 = - 105.3* (c=0.243, DMSO). RMN 'H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.45 (d, 1H) ; 9.35 (s, 1H) ; 8.6 (d, 1H) ; 8.20-7.90 (m, 5H) ; 7.60-7.10 (m, 4H); 5.30-5.10 ( m, 1H) ; 4.00 (t, 2H) ; 2.40-2.20 (m, 1H) ; 2.10-1.80 (m, 3H). Example 9 (Compound No. 60 of table 1) (+) 2-Methoxy-N-(9-methyl-4-oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H pyrido[1,2-a]pyrimidin-9-yl)-nicotinamide 9.1. (+) 5-amino-5-methyl-3-pyrimidin-4-yl-6,7,8,8a-tetrahydronaphthalen-1(5H) one WO 2008/078196 PCT/IB2007/004409 46 9.05g (35.17 mmol) of (+/-) 5-amino-5-methyl-3-pyrimidin-4-yl-6,7,8,8a tetrahydronaphthalen-1(5H)-one (compound 6.4 of example 6) was separated by chiral preparative HPLC (Daicel CHIRALCELL OD-1 20pm 50x220) eluting with a mixture of heptane/dichlomethane/methanol/diisopropylamine in the proportion 65/30/5/3 to give 3.64g of pure product obtained in the form of free base. tR: 22.0 min. Mp. : 162-163*C. [a]D 20 = + 63.660 (c=0.386, DMSO). RMN 1 H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.25 (s, 1H) ; 9.00 (d, 1H) ; 8.40 (d, 2H) ; 7.15 (s, 1H) ; 4.00-3.70 (m, 2H) ; 2.30 (br s, 2H) ; 2.10-1.70 (m, 3H) ; 1.45 (s, 3H). 9.2 (+) 2-Methoxy-N-(9-methyl-4-oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H pyrido[1,2-a]pyrimidin-9-yl)-nicotinamide By analogy with the method described in example 3 (step 3.7), using (+) 5-amino 5-methyl-3-pyrimidin-4-yl-6,7,8,8a-tetrahydronaphthalen-1 (5H)-one (step 9.1) and 2-methoxynicotinic acid, the compound, 0.167g (55%), was obtained as a white powder. Mp. : 150-152*C. [a]D 20 = +102.5 (c=0.727, DMSO). RMN 'H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.25 (s, 1H) ; 8.80 (s, 1H) ; 8.75 (d, 1H) ; 8.40-8.25 (m, 2H) ; 8.10 (dd, 1H) ; 7.50 (s, 1H) ; 7.15 (t, 1H) ; 4.55 (dd, 1H) ; 4.15 (s, 3H) ; 3.90-3.70 (m, 1H); 2.80-2.60 (m, 1H) ; 2.40-2.15 (m, 2H) ; 2.14-1.90 (m, 1H) ; 1.85 (s, 3H). Example 10 (Compound No. 61 of table 1) (-) 2-Methoxy-N-(9-methyl-4-oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahyd ro-4H pyrido[1,2-a]pyrimidin-9-yl)-nicotinamide 10.1 (-) 5-amino-5-methyl-3-pyrimidin-4-yl-6,7,8,8a-tetrahydronaphthalen-1(5H) one 9.05g (35.17 mmol) of (+/-) 5-amino-5-methyl-3-pyrimidin-4-yl-6,7,8,8a tetrahydronaphthalen-1 (5H)-one (compound 6.4 of example 6) was separated by chirale preparative HPLC (Daicel CHIRALCELL OD-1 20pm 50x220) eluting with a mixture of heptane/dichlomethane/methanol/diisopropylamine in the proportion 65/30/5/3 to give 4.18g of pure product obtained in the form of free base. tR : 8.0 WO 2008/078196 PCT/IB2007/004409 47 min. Mp. : 150-151"C. [a]D 20 = -57.71* (c=0.322, DMSO). RMN 'H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.25 (s, 1H) ; 9.00 (d, 1H) ; 8.40 (d, 2H) ; 7.15 (s, 1H) ; 4.00-3.70 (m, 2H) ; 2.30 (br s, 2H) ; 2.10-1.70 (m, 3H) ; 1.45 (s, 3H). 10.2 (-) 2-Methoxy-N-(9-methyl-4-oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahyd ro-4H pyrido[1,2-a]pyrimidin-9-yl)-nicotinamide By analogy with the method described in example 3 (step 3.7), using (-) 5-amino 5-methyl-3-pyrimidin-4-yl-6,7,8,8a-tetrahydronaphthalen-1 (5H)-one (step 10.1) and 2-methoxynicotinic acid, the compound, 0.130g (43%), was obtained as a white powder. Mp. : 139-141*C. [a]D 20 = - 102.70 (c=0.823, DMSO). RMN 1 H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.25 (s, 1H) ; 8.80 (s, 1H) ; 8.75 (d, 1H) ; 8.40-8.25 (m, 2H) ; 8.10 (dd, 1H) ; 7.50 (s, 1H) ; 7.15 (t, 1H) ; 4.55 (dd, IH) ; 4.15 (s, 3H) ; 3.90-3.70 (m, 1H); 2.80-2.60 (m, 1H) ; 2.40-2.15 (m, 2H) ; 2.14-1.90 (m, 1H) ; 1.85 (s, 3H). Example 11 (Compound No. 62 of table) (+) [1,5]Naphthyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahydro 4H-pyrido[1,2-a]pyrimidin-9-yI)-amide 0.098g (0.25 mmol) of (+/-) [1,5]naphthyridine-2-carboxylic acid (4-oxo-2 pyrimidin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide (compound 44 of table) was separated by chirale preparative HPLC (Daicel CHIRALCELL OD-H 20pm 50x220) eluting with ethanol to give 0.025g of pure product obtained in the form of free base. tR : 1 4
.
3 5 min. Mp.: 282-284'C. [a]D20 = + 33.13* (c=0.154, DMSO). RMN 1 H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.60 (d, 1H) ; 9.30 (s, 1H) ; 9.10 (s, 1H) ; 8.90 (d, 1H) ; 8.60 (d, 1H); 8.50-8.40 (m, 2H) ; 8.10 (d, 1H) ; 7.90 (m, 1H) ; 7.25 (s, 1H) ; 5.25 (m, 1H) 4.00 (t, 2H) ; 2.40 (m, 1H) ; 2.10 (m, 3H). Example 12 (Compound No. 63 of table 1) (-) [1,5]Naphthyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahydro- WO 2008/078196 PCT/IB2007/004409 48 4H-pyrido[1,2-a]pyrimidin-9-yl)-amide 0.098g (0.25 mmol) of (+/-) [1,5]naphthyridine-2-carboxylic acid (4-oxo-2 pyrimidin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide (compound 44 of table) was separated by chirale preparative HPLC (Daicel CHIRALCELL OD-H 20pm 50x220) eluting with ethanol to give 0.023g of pure product obtained in the form of free base. tR: 1 2
.
52 min. Mp. : 272-274 0 C. [aD 20 = - 26.84* (c=0.211, DMSO). RMN 'H (DMSO-d 6 ; 200MHz) 6 (ppm) : 9.60 (d, 1H) ; 9.30 (s, 1H) ; 9.10 (s, 1H) ; 8.90 (d, 1H) ; 8.60 (d, 1H); 8.50-8.40 (m, 2H) ; 8.10 (d, 1H) ; 7.90 (m, 1H) ; 7.25 (s, 1H) ; 5.25 (m, 1H) 4.00 (t, 2H) ; 2.40 (m, 1H) ; 2.10 (m, 3H). Example 13 (Compound No. 104 of table 3) (+) 2-Methoxy-N-(10-methyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide 13.1 2-Pyrimidin-4-yl-7,8,9,1 0-tetrahydro-6H-pyrimido[1,2-a]azepin-4-one To a suspension of 77.9g (524.1 mmol) of 2H-azepin-7-amine, 3,4,5,6-tetrahydro, monohydrochloride (synthesis as described in W096/14844 or Journal of Medicinal Chemistry (1998), 41(9), 1361-1366 or by analogy with the method described in example 1, step 1.1. and 1.2 using E-caprolactam instead of (+/-)-3 phthalimidopiperidin-2-one) in 390 mL of ethanol was added 72.4g (524.1 mmol) of potassium carbonate. The reaction mixture was stirred at room temperature for 10 min, 101.7g (524.1 mmol) of ethyl 3-(4-pyrimidinyl)-3-oxopropionate was added and the resulting mixture was stirred under reflux for 16h. The cooled solution was evaporated to remove solvent. The mixture was dissolved in dichloromethane, washed with a saturated aqueous solution of sodium chloride, dried over sodium sulfate and evaporated to dryness. The residue was filtrate through a pad of silica, rinsing with dichloromethane and then ethyl acetate. After evaporation, the resulting solid was triturated with diethyl ether to afford 36.4g (28%) of pure product as a white-brown powder. Mp: 148-150'C. RMN 'H (DMSO-d 6 ; 400 MHz) 6 (ppm) : 9.32 (s, 1H), 9.01 (d, 1H), 8.24 (d, 1H), 7.21 (s, 1H), 4.32 (m, 2H), 3.11 (m, 2H), 1.66-1.83 (m, 6H).
WO 2008/078196 PCT/IB2007/004409 49 13.2 (+-) 1 0-Methyl-2-pyrimidin-4-yl-7,8,9,1 0-tetrahydro-6H-pyrimido[1,2 a]azepin-4-one To a solution of 26.1g (107.73 mmol) of 2-pyrimidin-4-yl-7,8,9,10-tetrahydro-6H pyrimido[1,2-a]azepin-4-one in dry tetrahydrofuran (450 mL) under argon at - 78 *C was added 82.5 mL (82.5 mmol) of lithium bis(trimethylsilyl)amide (1M in tetrahydrofuran). The solution was stirred at -78"C for 10 min and 25.7 mL of methyl iodide (412.7 mmol) was added. The reaction was stirred at -78 0 C for 1 h and then at 0*C for 2h. The mixture was quenched with the addition of a saturated solution of ammonium chloride and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated. The residue was chromatographed on silica gel eluting with a mixture of dichloromethane/methanol in the proportions 99/1 to afford 11.0g (40%) of the desired compound as a white solid. Mp: 184-186*C. RMN 1 H (DMSO-d 6 ; 400 MHz) 6 (ppm) : 9.31 (s, 1H), 9.03 (d, 1H), 8.30 (d, 1H), 7.22 (s, 1H), 5.02 (m, 1H), 3.70 (m, 1H), 3.40 (m, 1H), 2.00 (m, 1H), 1.78-1.90 (m, 3H), 1.30-1.48 (m, 5H). 13.3 (+/-) 10-Amino-1 0-methyl-2-pyrimidin-4-yl-7,8,9,1 0-tetrahydro-6H pyrimido[1,2-a]azepin-4-one To a solution of 10.Og (39.0 mmol) (+/-) 10-methyl-2-pyrimidin-4-yl-7,8,9,10 tetrahydro-6H-pyrimido[1,2-a]azepin-4-one in a mixture of dry tetrahydrofuran/ dimethyltetrahydropyrimidinone (150/20 mL) under argon at -78*C was added 81.9 mL (81.9 mmol) of lithium bis(trimethylsilyl)amide (1M in tetrahydrofuran). The solution was stirred at -78*C for 5 min. The solution was warmed to 0*C by changing the cold bath and 13.3g (42.9 mmol) of 2,4,6-triisopropylbenzene sulfonyl azide in 30 mL of dry tetrahydrofuran was added. The reaction was stirred at 0*C for 1h, at room temperature for 1h and 10.0 mL (175.6 mmol) of acetic acid was added. The mixture was stirred at room temperature for 1h and then diluted with ethyl acetate. The organic phase was washed with water and a saturated solution of sodium chloride, dried over sodium sulfate and concentrated to afford 1 0-azido-1 0-methyl-2-pyrimidin-4-yl-7,8,9,1 0-tetrahydro-6H-pyrimido[1,2-a]azepin- WO 2008/078196 PCT/IB2007/004409 50 4-one as an orange oil. The compound was used as such in the next step. A mixture of 23.9 mL (234.1 mmol) of thiophenol, 11.1g (58.5 mmol) of tin (II) chloride and 24.5 mL (175.6 mmol) triethylamine in acetonitrile (300 mL) was stirred for 5 min at room temperature. 10-Azido-10-methyl-2-pyrimidin-4-yl 7,8,9,10-tetrahydro-6H-pyrimido[1,2-a]azepin-4-one residue diluted in 90 mL of acetonitrile was added to this solution and the mixture was stirred for 1h. A solution of sodium hydroxide (1M) was added and the mixture extracted with dichloromethane. After an acido-basic work-up, the residue was chromatographed on silica gel eluting with a mixture of dichloromethane/methanol in the proportions 95/5 to afford 6.3g (58%) of a yellow solid. Mp: 139-141*C. RMN 1 H (DMSO-d 6 ; 400 MHz) 6 (ppm) : 9.40 (s, 1H), 9.18 (d, 1H), 8.85 (br s, 2H), 8.68 (d, 1H), 7.38 (s, 1H), 5.18 (m, 1H), 3.62 (m, 1H), 3.20 (m, 1H), 2.23-1.75 (m, 4H), 1.83 (s, 3H), 1.50 (m, 1 H). 13.4 (+) 10-Amino-I 0-methyl-2-pyrimidin-4-yl-7,8,9,1 0-tetrahydro-6H pyrimido[1,2-a]azepin-4-one 0.797g (2.94 mmol) of (+/-) 10-amino-10-methyl-2-pyrimidin-4-yl-7,8,9,10 tetrahydro-6H-pyrimido[1,2-a]azepin-4-one was separated by chirale preparative HPLC (Daicel Chiralcel AD 20 pm) eluting with ethanol to give 0.390g of pure product obtained in the form of free base. tR: 1 9 min. Mp. : 117-119 *C. [a]D 20 = + 42.50* (c=0.188, DMSO). RMN 1 H (DMSO-d 6 ; 400MHz) 6 (ppm) : 9.32 (s, 1H), 9.08 (d, 1H), 8.31 (d, 1H), 7.25 (s, 1H), 4.80 (m, 2H), 2.30 (br s, 2H), 2.03 (m, 1 H), 1.89 (m, 2H), 1.79 (m, 2H), 1.68 (s, 3H), 1.38 (m, 1 H). 13.5 (+) 2-Methoxy-N-(10-methyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide To a solution of 0.100g (0.37 mmol) of (+) 10-amino-10-methyl-2-pyrimidin-4-yl 7,8,9,10-tetrahydro-6H-pyrimido[1,2-a]azepin-4-one dissolved in 3 mL of dimethylformamide were added at 0*C, 0.056g (0.37 mmol) of 2-methoxy nicotinic acid, 0.070 mL (0.44 mmol) of diethylcyanophosphonate and 0.05 mL (0.37 mmol) of triethylamine. The resulting mixture was stirred at room temperature for 20h.
WO 2008/078196 PCT/IB2007/004409 51 Water and ethyl acetate were added, the mixture was extracted with ethyl acetate and the organic phase was washed with water and a saturated solution of ammonium chloride, dried over sodium sulfate and concentrated. After purification on silica gel, the residue was triturated with petroleum ether to give 0.056g (37%) of pure product obtained in the form of free base as a yellow solid. Mp : 109-111 C. [a]OD 20 = + 137.0 0 (c= 0.428, DMSO). RMN 1 H (DMSO-d 6 ; 400MHz) 6 (ppm) : 9.36 (d, 1H), 9.09 (d, 1H), 8.80 (s, 1H), 8.35 (m, 2H), 7.96 (m, 1H), 7.28 (s, 1H), 7.11 (m, 1H), 5.10 (m, 1H), 4.02 (s, 3H), 3.98 (m, 1H), 2.32 (m, 1H), 2.18 (m, 1H), 2.01 (m, 1H), 1.85 (s, 5H), 1.35 (m, 1H) . Example 14 (Compound No. 106 of table 3) 14.1 (-) 10-Amino-10-methyl-2-pyrimidin-4-yl-7,8,9,10-tetrahydro-6H-pyrimido[1,2 a]azepin-4-one 0.797g (2.94 mmol) of (+/-) 10-amino-10-methyl-2-pyrimidin-4-yl-7,8,9,10 tetrahydro-6H-pyrimido[1,2-a]azepin-4-one (step 13.3) was separated by chirale preparative HPLC (Daicel Chiralcel AD 20 pm) eluting with ethanol to give 0.384g of pure product obtained in the form of free base. tR: 38 min. Mp. : 117-119 "C. []D 2 0 = - 45.11 * (c= 0.235, DMSO). RMN 1 H (DMSO-d 6 ; 400MHz) 6 (ppm) : 9.32 (s, 1H), 9.08 (d, 1H), 8.31 (d, 1H), 7.25 (s, 1H), 4.80 (m, 2H), 2.30 (br s, 2H), 2.03 (m, 1 H), 1.89 (m, 2H), 1.79 (m, 2H), 1.68 (s, 3H), 1.38 (m, 1 H). 14.2 (-) 2-Methoxy-N-(1 0-methyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahyd ro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide By analogy with the method described in example 13 (step 13.5), using (-) 10 amino-1 0-methyl-2-pyrimidin-4-yl-7,8,9,1 0-tetrahydro-6H-pyrimido[1,2-alazepin-4 one in place of (+) 10-amino-10-methyl-2-pyrimidin-4-yl-7,8,9,10-tetrahydro-6H pyrimido[1,2-a]azepin-4-one, the compound, 0.048g (32%), was obtained as a white powder. Mp: 111*C (decomposition). [a]D 20 = -139.7 * (c= 0.373, DMSO).
WO 2008/078196 PCT/IB2007/004409 52 RMN 'H (DMSO-d 6 ; 400MHz) 6 (ppm) : 9.36 (d, 1H), 9.09 (d, 1H), 8.80 (s, 1H), 8.35 (m, 2H), 7.96 (m, 1H), 7.28 (s, 1H), 7.11 (m, 1H), 5.10 (m, 1H), 4.02 (s, 3H), 3.98 (m, 1H), 2.32 (m, 1H), 2.18 (m, 1H), 2.01 (m, 1H), 1.85 (s, 5H), 1.35 (m, 1H) . Example 15 (Compound No. 79 of table 3) (+/-) 2,3-Dihydro-benzofuran-7-carboxylic acid (10-methyl-4-oxo-2-pyridin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-alazepin-1 0-yl)-amide 15.1 2-Pyridin-4-yl-7,8,9,10-tetrahydro-6H-pyrimido[1,2-a]azepin-4-one By analogy with the method described in example 13 (step 13.1), using ethyl 3 (pyridin-4-yl)-3-oxopropionate in place of ethyl 3-(4-pyrimidinyl)-3-oxopropionate, 20.Og of the compound (54%) was obtained as a white powder. Mp: 148-150 'C. RMN 'H (DMSO-d 6 ; 400MHz) 6 (ppm) : 8.79 (d, 2H), 8.01 (d, 2H), 7.08 (s, 1H), 4.31 (m, 2H), 3.11 (m, 2H), 1.80 (m, 4H), 1.78 (m, 2H). 15.2 (+/-) 10-Methyl-2-pyridin-4-yl-7,8,9,10-tetrahydro-6H-pyrimido[1,2-a]azepin 4-one By analogy with the method described in example 13 (step 13.2), using 2-pyridin 4-yl-7,8,9,10-tetrahydro-6H-pyrimido[1,2-a]azepin-4-one in place of 2-pyrimidin-4 yI-7,8,9,10-tetrahydro-6H-pyrimido[1,2-a]azepin-4-one, 1.13g of the compound (21%) was obtained as a orange powder. Mp: 137-139 0 C. RMN 'H (DMSO-dr; 400MHz) 6 (ppm) : 8.72 (d, 2H), 8.08 (d, 2H), 7.09 (s, 1H), 5.01 (m, 1H), 3.68 (m, 1H), 3.37 (m, 2H), 1.98 (m, 1 H), 1.83 (m, 2H), 1.49-1.25 (m, 5H). 15.3 (+/-) 2,3-Dihydro-benzofuran-7-carboxylic acid (10-methyl-4-oxo-2-pyridin-4 yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide WO 2008/078196 PCT/IB2007/004409 53 By analogy with the method described in example 13 (step 13.3), using (+/-) 10 methyl-2-pyridin-4-yl-7,8,9,1 0-tetrahydro-6H-pyrimido[1,2-a]azepin-4-one in place of (+/-) 1 0-methyl-2-pyrimidin-4-yl-7,8,9, 1 0-tetrahydro-6 H-pyrimido[ 1,2-a]azepin-4 one, 1 0-azido-1 0-methyl-2-pyridin-4-yl-7,8,9,1 0-tetrahydro-6H-pyrimido[1,2 a]azepin-4-one was obtained. The compound was used as such in the next step. 1 0-azido-1 0-methyl-2-pyridin-4-yl-7,8,9,1 0-tetrahydro-6H-pyrimido[1,2-a]azepin-4 one was reduced by using H-CubeTM technology (from THALES Nanotechnology, full H 2 , Pd/C as catalyst, 1mL/min and 50'C). After an acido-basic work-up, (+/-) 10-amino-1 0-methyl-2-pyridin-4-yi-7,8,9,1 0-tetrahydro-6H-pyrimido[1,2-a]azepin 4-one was obtained and the compound was used as such in the next step. By analogy with the method described in example 13 (step 13.5) by using 2,3 dihydrobenzofuran-7-carboxylic acid and (+/-) 10-amino-10-methyl-2-pyridin-4-yl 7,8,9,10-tetrahydro-6H-pyrimido[1,2-a]azepin-4-one instead of 2-methoxy nicotinic acid and (+) 10-amino-1 0-methyl-2-pyrimidin-4-yl-7,8,9,1 0-tetrahydro-6H pyrimido[1,2-a]azepin-4-one, 76mg (39%) of a white compound was obtained. Mp: 213-214"C. RMN 'H (DMSO-d 6 ; 400MHz) 6 (ppm) : 8.75 (d, 2H), 8.38 (br s, 1H), 8.08 (d, 2H), 7.52 (d, 1H), 7.45 (d, 1H), 7.15 (s, 1H), 6.95 (t, 1H), 5.02 (m, 1H), 4.80 (m, 2H), 3.80 (m, 1H), 3.30 (m, 4H), 2.32 (m, 1H), 2.13-1.80 (m, 2H), 1.88 (s, 3H), 1.35 (m, 1H). Example 16 (Compound No. 93 of table 3) (+/-) 4-Methoxy-pyridine-2-carboxylic acid (1 0-ethyl-4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide 16.1 (+/-) 10-Ethyl-2-pyrimidin-4-yl-7,8,9,10-tetrahydro-6H-pyrimido[1,2-a]azepin 4-one By analogy with the method described in example 13 (step 13.2), using ethyl iodide instead of methyl iodide, 0.46g of the compound (21%) was obtained as a white powder. Mp: 128-130*C.
WO 2008/078196 PCT/IB2007/004409 54 RMN 'H (DMSO-d 6 ; 400MHz) 6 (ppm) : 9.32 (s, 1H), 9.08 (d, 1H), 8.27 (d, 1H), 7.22 (s, 1H), 4.98 (m, 1H), 3.78 (m, 1H), 3.12 (m, 1H), 2.15 (m, 1H), 1.95 (m, 2H), 1.80 (m, 2H), 1.60 (m, IH), 1.35 (m, 2H), 1.08 (t, 3H). 16.2 (+/-) 10-Amino-10-ethyl-2-pyrimidin-4-yl-7,8,9,10-tetrahydro-6H-pyrimido[1,2 a]azepin-4-one By analogy with the method described in example 13 (step 13.3), using 10-ethyl 2-pyrimidin-4-yl-7,8,9,10-tetrahydro-6H-pyrimido[1,2-a]azepin-4-one in place of 1 0-methyl-2-pyrimidin-4-yl-7,8,9,1 0-tetrahydro-6H-pyrimido[1,2-a]azepin-4-one, 0.83g of the compound (46%) was obtained as a orange oil. RMN 1 H (DMSO-d 6 ; 400MHz) 6 (ppm) : 9.32 (s, 1H), 9.08 (d, 1H), 8.32 (d, 1H), 7.28 (s, IH), 4.91 (m, 1H), 4.40 (m, 1H), 2.01 (m, 2H), 1.85-1.50 (m, 6H), 0.98 (t, 3H) 16.3 (+/-) 4-Methoxy-pyridine-2-carboxylic acid (10-ethyl-4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide By analogy with the method described in example 13 (step 13.5), using (+/-) 10 amino-1 0-ethyl-2-pyrimidin-4-yl-7,8,9, 1 0-tetrahydro-6H-pyrimido[1,2-a]azepin-4 one and 4-methoxy-pyridine-2-carboxylic acid in place of (+) 10-amino-i 0-methyl 2-pyrimidin-4-yl-7,8,9,1 0-tetrahydro-6H-pyrimido[1,2-a]azepin-4-one and 2 methoxy nicotinic acid, 37mg (31%) of the compound was obtained as a white solid. Mp: 200-202*C. RMN 1 H (DMSO-d 6 ; 400MHz) 6 (ppm) : 10.20 (br s, 1H), 9.38 (s, 1H), 9.25 (d, 1H), 8.68 (d, 1H), 8.61 (m, 1H), 7.58 (s, 1H), 7.34 (s, 1H), 7.22 (m, 1H), 4.50 (m, 1H), 4.32 (m, 1H), 3.92 (s, 3H), 2.58 (m, 2H), 2.32 (m, 2H), 1.90 (m, 2H), 1.71 (m,2H), 0.81 (t, 3H). Example 17 (Compound No. 100 of table 3) (+/-) N-(3-Bromo-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2 a]azepin-1 0-yl)-2-methoxy-nicotinamide 17.1 (+/-) (3-Brom o-4-oxo-2-pyri midin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1, 2 a]azepin-10-yl)-carbamic acid ethyl ester WO 2008/078196 PCT/IB2007/004409 55 0.3g (1.17 mmol) of (+/-) 1 0-amino-2-pyrimidin-4-yl-7,8,9,10 tetrahydropyrimido[1,2-a]azepin-4(6H)-one (compound 3.4 of example 3) was diluted in 8 mL of tetrahydrofuran. 0.18 mL (1.28 mmol) of triethylamine was added at 0*C and the mixture was stirred for 10 min and 0.12 mL (1.28 mmol) of ethyl chloroformate was added. The resulting mixture was stirred at room temperature for 1h and quenched by adding a saturated solution of ammonium chloride. The product was extracted with dichloromethane, dried over sodium sulfate and the solvent was evaporated. The residue was triturated with diethyl ether and filtered to afford 0.28g (72%) of (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-carbamic acid ethyl ester as a yellow solid (Mp. : 168-170*C). The compound was used as such in the next step. To a solution of 0.080g (0.24 mmol) of (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-carbamic acid ethyl ester in dimethylformamide (4 mL) were added 0.21g (1.21 mmol) of N-bromosuccinimide and 0.03g (0.12 mmol) of benzoyl peroxide. The solution was stirred at room temperature for 10 min and at 500C for 20 min. The reaction was quenched by adding a saturated solution of ammonium chloride. The product was extracted with dichloromethane, the organic phase was washed with a saturated solution of sodium chloride, dried over sodium sulfate, filtered and the solvent was evaporated. The residue was chromatographed on silica gel eluting with a mixture of dichloromethane/methanol in the proportions 95/5 to afford 58 mg of a solid. Mp: 72-74C RMN 1 H (DMSO-d 6 ; 400MHz) 6 (ppm) : 9.42 (s, 1H), 9.12 (d, 1H), 7.92 (d, 1H), 7.51 (m, 1H), 5.01 (m, 2H), 4.08 (m, 2H), 3.92 (m, 1H), 2.08-1.71 (m, 5H), 1.52 (m, 1H), 1.20 (m, 3H) 17.2 (+/-) N-(3-Bromo-4-oxo-2-pyrimidin-4-yI-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-yl)-2-methoxy-nicotinamide To a solution of 0.34 g (0.84 mmol) of (+/-) (3-bromo-4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin-10-yl)-carbamic acid ethyl ester in 2 mL of acetic acid was added 0.78 mL (4.21 mmol) of a solution of hydrobromic acid (5.7N in acetic acid). The reaction was stirred at 100*C for 3h. The solvent was evaporated and an acido-basic work-up gave 65 mg (33 %) of 10-amino-3 bromo-2-pyrimidin-4-yl-7,8,9,10-tetrahydro-6H-pyrimido[1,2-a]azepin-4-one as an orange oil. The compound was used as such in the next step. By analogy with the method described in example 13 (step 13.5), using (+/-) 10- WO 2008/078196 PCT/IB2007/004409 56 amino-3-bromo-2-pyrimidin-4-yl-7,8,9,1 0-tetrahydro-6H-pyrimido[1,2-a]azepin-4 one in place of (+) 10-amino-10-methyl-2-pyrimidin-4-yl-7,8,9,10-tetrahydro-6H pyrimido[1,2-a]azepin-4-one; 40mg (49 %) of the titled compound was obtained as a white solid. Mp: 190-192*C. RMN 1 H (DMSO-d 6 ; 400MHz) 5 (ppm) : 9.58 (m, 1H), 9.48 (s, 1H), 9.12 (d, 1H), 8.38 (m, 2H), 7.95 (d, 1H), 7.21 (m, 1H), 5.41 (m, 1H), 5.08 (m, 1H), 3.90 (m, IH), 3.62 (s, 3H), 2.20 (m, 1H), 2.08-1.95 (m, 3H), 1.75 (m, 1H), 1.48 (m, 1H). Example 18 (Compound No. 105 of table 3) (-) 2,6-Dimethoxy-N-(10-methyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide By analogy with the method described in example 14 (step 14.2), using 2,4 dimethoxy nicotinic acid in place of 2-methoxy nicotinic acid, the compound, 0.082g (51%), was obtained as a white powder. Mp: 114 "C decomposition. [a]D 20 = -197.2 o (c= 0.460, DMSO). RMN 'H (DMSO-d 6 ; 400MHz) 6 (ppm) : 9.32 (s, 1H), 9.08 (d, 1H), 8.48 (s, 1H), 8.30 (m, 1H), 8.00 (d, 1H), 7.25 (s, 1H), 6.50 (d, 1H), 5.08 (m, 1H), 4.10 (s, 3H), 3.98 (s, 3H), 3.85 (m, 1H), 2.32 (m, 1H), 2.20-1.88 (m, 2H), 1.88 (m, 5H), 1.32 (m, 1H). Example 19 (Compound No. 107 of table 3) (+) 2,6-Dimethoxy-N-(10-methyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide By analogy with the method described in example 13 (step 13.5), using 2,4 dimethoxy nicotinic acid in place of 2-methoxy nicotinic acid, the compound, 0.066g (41%), was obtained as a white powder. Mp : 89-91*C. [a]D 20 = + 196.6 * (c= 0.405, DMSO). RMN 'H (DMSO-d 6 ; 400MHz) 6 (ppm) : 9.32 (s, 1H), 9.08 (d, 1H), 8.48 (s, 1H), 8.30 (m, 1H), 8.00 (d, 1H), 7.25 (s, 1H), 6.50 (d, 1H), 5.08 (m, 1H), 4.10 (s, 3H), 3.98 (s, 3H), 3.85 (m, 1H), 2.32 (m, 1H), 2.20-1.88 (m, 2H), 1.88 (m, 5H), 1.32 (m, 1H). Example 20 (Compound No. 102 of table 3) (+) 2,6-Dimethoxy-pyrimidine-4-carboxylic acid (4-oxo-2-pyrimidin-4-yl- WO 2008/078196 PCT/IB2007/004409 57 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide By analogy with the method described in example 13 (step 13.5), using (+) 10 amino-2-pyrimidin-4-yl-7,8,9,10-tetrahydropyrimido[1,2-a]azepin-4(6H)-one (step 3.5 of example 3) and 2,4-dimethoxy nicotinic acid in place of (+) 10-amino-10 methyl-2-pyrimidin-4-yl-7,8,9,1 0-tetrahydro-6H-pyrimido[1,2-a]azepin-4-one and 2-methoxy nicotinic acid. The compound, 0.903g (69%), was obtained as a powder. Mp: 199-200*C. [a]D20 = + 25.34 * (c= 0.266, DMSO). RMN 1 H (DMSO-d 6 ; 400MHz) 6 (ppm) : 9.48 (s, 1H), 9.35 (m, 1H), 9.22 (d, 1H), 8.38 (m, 2H), 7.35 (s, 1H), 6.62 (d, 1H), 5.51 (m, 1H), 5.10 (m, 1H), 4.20 (s, 3H), 4.02 (s, 3H), 3.78 (m, 1H), 2.25 (m, 1H), 2.12-1.95 (m, 3H), 1.75 (m, 1H), 1.41 (m, 1H). Example 21 (Compound No. 103 of table 3) (-) 2,6-Dimethoxy-pyrimidine-4-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide By analogy with the method described in example 13 (step 13.5), using (-) 10 amino-2-pyrimidin-4-yl-7,8,9,10-tetrahydropyrimido[1,2-a]azepin-4(6H)-one (step 3.6 of example 3) and 2,4-dimethoxy nicotinic acid in place of (+) 10-amino-10 methyl-2-pyrimidin-4-yl-7,8,9,1 0-tetrahydro-6H-pyrimido[1,2-a]azepin-4-one and 2-methoxy nicotinic acid, the compound, 0.85g (64%), was obtained as a powder. Mp: 200-202*C. [a]o 2 0 = - 29.93 * (c= 0.426, DMSO). RMN 'H (DMSO-d 6 ; 400MHz) 6 (ppm) : 9.48 (s, 1H), 9.35 (m, 1H), 9.22 (d, 1H), 8.38 (m, 2H), 7.35 (s, 1H), 6.62 (d, 1H), 5.51 (m, 1H), 5.10 (m, 1H), 4.20 (s, 3H), 4.02 (s, 3H), 3.78 (m, 1H), 2.25 (m, 1H), 2.12-1.95 (m, 3H), 1.75 (m, 1H), 1.41 (m, 1H). Example 22 (Compound No. 108 of table 3) (-) 5-Bromo-2,3-dihydro-benzofuran-7-carboxylic acid (1 0-methyl-4-oxo-2 pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide By analogy with the method described in example 14 (step 14.2), using 5-bromo 2,3-dihydro-benzofuran-7-carboxylic acid in place of 2-methoxy nicotinic acid, the compound, 0.075g (35%), was obtained as a white powder. Mp: 126"C (decomposition). [aiD 20 = -144.2 0 (c= 0.449, DMSO). RMN 'H (DMSO-d 6 ; 400MHz) WO 2008/078196 PCT/IB2007/004409 58 6 (ppm) : 9.35 (d, 1H), 9.10 (d, 1H), 8.45 (m, 1H), 8.32 (d, IH), 7.65 (s, 1H), 7.55 (s, 1H), 7.30 (s, 1H), 5.02 (m, 1H), 4.85 (m, 2H), 3.81 (m, 1H), 3.81 (m, 1H), 2.31 (m, 1H), 2.15-1.82 (m, 5H), 1.90 (s, 3H), 1.35 (m, 1H). Example 23 (Compound No. 109 of table 3) (+) 5-Bromo-2,3-dihydro-benzofuran-7-carboxylic acid (1 0-methyl-4-oxo-2 pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide By analogy with the method described in example 13 (step 13.5), using 5-bromo 2,3-dihydro-benzofuran-7-carboxylic acid in place of 2-methoxy nicotinic acid, the compound, 0.022g (8%), was obtained as a white powder. Mp: 176-178*C. [aD 2 0 = +146.3 * (c= 0.330, DMSO). RMN 1 H (DMSO-d 6 ; 400MHz) 6 (ppm) : 9.35 (d, 1H), 9.10 (d, 1H), 8.45 (m, 1H), 8.32 (d, 1H), 7.65 (s, 1H), 7.55 (s, 1H), 7.30 (s, 1H), 5.02 (m, 1H), 4.85 (m, 2H), 3.81 (m, 1H), 3.81 (m, 1H), 2.31 (m, 1H), 2.15-1.82 (m, 5H), 1.90 (s, 3H), 1.35 (m, 1H). A list of chemical structures and physical data for compounds of the aforementioned formula (1), illustrating the present invention, is given in table 1. The compounds have been prepared according to the methods of the examples. In the table, m and o represent 1, Ph represents a phenyl group, (dec.) indicates the decomposition of the compound, (Rot.) indicates the levorotatory or dextrorotatory properties of the enantiomeric compound. The nomenclature is given according to IUPAC recommendations. R1 R3 R7 R6NI R2z N N 0 Y m )o R4 R5 (1) WO 2008/078196 PCT/IB2007/004409 59 Table 1 No. Rot R2 Z RI R4 R5 R6 R7 Y R3 n Mp "C salt N CHN CH, b 1 (+/-) bond y H H H H 0 H 0 200-202 Free base N 2 (+/-) bond H H H H 0 H 0 267-269 Free base bond e H H H H 0 H 029-6Frebs N N 3 +F)bond -- H H H H 0 H 0 253-255 Free base 6 bond eH H H H O H 0 194-196 Free base N 7 (+-Dond H H H H O H 0 260-262 Free base 4 (+/-) CH bond -N H H H H 0 H 0 24-296 Free base N 5 (+/) H bond N H H H H 0 H 0 223-236 Freebase N N 6 bond N H H H H 0 H 0 219-21 Free base 7 1 -) bond -~ H H H H 0 H 0 2 6-2 62 Free base N 91 A+1 bond y H H H H 0 H 0 240-242 Free base 0. I WO 2008/078196 PCT/IB2007/004409 60 No. Rot R2 Z R1 R4 R5 R6 R7 Y R3 n Mp C salt N 12 (+/-) bond y H H H H 0 H 0 112-114 Free base N 13 (+/-) bond H H H H 0 H 0 293-295 Free base N N 14 (+/-) bond N H H H H 0 H 0 225-227 Free base N N 15 (+/-) * bond - H H H H 0 H 0 177-179 Free base N 1 (+/-) bond N H H H H 0 H 0 196-198 Free base 0 N 17 (+- 3. bond -~N H H H H 0 H 0 264-266 Free base 18 (+- 'I$'bond AN H H H H 0 H 0 262-264 Free base 19 (+/-) bond N H H H H 0 H 0 251-254 Free base NN 20 (-4)bond AN H H H H 0 H 0 259-262 Free base 21 (-) c bond AN H H H H 0 H 0 220-223 Free base 22 (1)bond AN H H H H 0 H 0 217-220 Free base WO 2008/078196 PCT/IB2007/004409 61 No. Rot R2 Z R1 R4 R5 R6 R7 Y R3 n Mp C salt 23 (+/-) bond N H H H H 0 H 0 225-228 Free base 24 bond N H H H H 0 H 0 210-213 Free base 2b5 bond N H H H H 0 H 0 126-129 Free base CNN 26 (+/-) bond H H H H 0 H 0 251-253 Free base N 27 (+/-) bond N H H H H 0 H 0 207-210 Free base 28 (+/-) bond N H H H H 0 H 0 256-259 Free base N 29 (+/-) bond N H H H H 0 H 0 168-172 Free base 30 Hc bond N H H H H O H 0 226-228 Free base H N 31 (+/-) bond H H H H 0 H 0 203-205 Free base N 32 (+/-) bond N H H H H 0 H 0 207-209 Free base CI N 32 bond N H H H H 0 H 0 256-259 Free base Ha N NN 34 (+-) bond /N H H CH 3 H 0 H 0 193-195 Free base WO 2008/078196 PCT/IB2007/004409 62 No. Rot R2 Z RI R4 R5 R6 R7 Y R3 n Mp *C salt c CN 35 (+/-) bond N H H H H 0 H 0 237-239 Free base N NN 36 (+/-) bond N H H H H 0 H 0 244-246 Free base 37 (+/-) bond N H H H H 0 H 0 260-262 Free base 38 (+/-) bond N H H H H 0 H 0 262 Free base (dec.) 39 (+/-) bond N H H H H 0 H 0 288-290 Free base 40 (+/-) bond N H H H H 0 H 0 266-268 Free base 5 CH, N N N 41 (+/-) bond H H CH 3 H 0 H 0 238-240 Free base CI 42 (+/-) N N H H H H 0 H 0 283-285 Free base N 300 43 (+-) bond N H H H H 0 H 0 Free base (dec.) N-.. I'287 44 (+/-) N bond H H H H 0 H 0 Free base 45 (+/-) bond N H H H H 0 H 0 Free base (dec.) WO 2008/078196 PCT/IB2007/004409 63 No. Rot R2 Z R1 R4 R5 R6 R7 Y R3 n Mp C salt NN F 46 (+/-) N bnd N H H H H 0 H 0 210-212 Free base 47 (+/-) bond N H H CH 3 H 0 H 0 283-285 Free base N 48 (+1-) bond N H H CH 3 H 0 H 0 218-220 Freebase 49 (+/-) C bond N H H CH 3 H 0 H 0 191-193 Freebase 5bond ,NN H H CH 3 H 0 H 0 198-200 Freebase 0 O 51 (+/-) bond N H H CH 3 H 0 H 0 289-291 Free base 52 bond N H H CH 3 H 0 H 0 276-278 Free base 6 b N 53 (+/-) bond ~ -N H H CH 3 H 0 H 0 251-272 Free base N 54 (+/-) N bod~N H H OH 3 H 0 H 0 270-27 Free base 55 (+/-) N bond -N H H CH 3 H 0 H 0 235-237 Free base WO 2008/078196 PCT/IB2007/004409 64 No. Rot R2 Z RI R4 R5 R6 R7 Y R3 n Mp"C salt 57 (+/-) bond H H CH 3 H 0 H 0 278-280 Free base N F K 58 (+) N bond N H H H H 0 H 0 200-202 Free base 59 (-) N bond .N H H H H 0 H 0 199-200 Free base N 60 (-) N YObond N H H CH 3 H 0 H 0 150-152 Freebase HN 61 (-) bond N H H cH 3 H 0 H 0 139-141 Freebase 62 (bond H H H H H 0 282-284 Freebase 63 (-) bond H H H H 0 H 0 272-274 Free base A list of chemical structures and physical data for compounds of the aforementioned formula (I), illustrating the present invention, is given in table 2. The compounds have been prepared according to the methods of the examples. In the table, m represents 0 and o represents 1, (Rot.) indicates the levorotatory or dextrorotatory properties of the enantiomeric compound.
WO 2008/078196 PCT/IB2007/004409 65 R1 R3 R7 R6 N R R2 z f N N O Y m )o R4 R5 (I) Table 2 No. Rot R2 Z R1 R4 R5 R6 R7 Y R3 n Mp *C salt N (+/-) bond y H H H H 0 H 0 206-208 Free base N 2 (+/-) bond H H H H 0 H 0 393-395 Free base N N 3 (+/-) bond H H H H 0 H 0 291-293 Free base N F I
N
+ r bond H H H H 0 H 0 183-185 Free base N 5 (+/-) bond H H H H 0 H 0 238-240 Free base N 6 (+/-) bond H H H H 0 H 0 149-151 Freebase N 7 N+- bond - H H H H 0 H 0 170-172 Free base CHy WO 2008/078196 PCT/IB2007/004409 66 No. Rot R2 Z R1 R4 R5 R6 R7 Y R3 n Mp C salt N 8 (+/-) bond H H H H 0 H 0 240-242 Free base -b N 9 (+-) bond - H H H H 0 H 0 110-112 Free base N 10 bond N H H H H 0 H 0 101-103 Free base N N 11 (+f-) bond N H H H H 0 H 0 233-235 Free base II 283 12 (+/-) bond H H H H 0 H 0 Free base 16 ()n(dec.) CH 13 (+/-) bond H H H H 0 H 0 264-266 Free base CH 14 bond H H H H 0 H 0 232-234 Free base ci 15 (-)bond ~ N H H H H 0 H 0 226-228 Frebs N 16 (+N- 1 bnd H H H H 0 H 0 244 Free base bon (dec.) N CH, N 17 N-1- N bond - H H H H 0 H 0 260-263 Free base cl N 18 D+- V ond I~ H H H H 0 H 0 230-232 Free base WO 2008/078196 PCT/IB2007/004409 67 No. Rot R2 Z R1 R4 R5 R6 R7 Y R3 n Mp C salt 19 (+/) bond H H H H 0 H 0 187-190 Free base N - N 21 Free base 20 (+/-) bond Y H H H H 0 H 0 201c.) N 21 (+/-) bond Y H H H H 0 H 0 242-244 Free base A list of chemical structures and physical data for compounds of the aforementioned formula (I), illustrating the present invention, is given in table 3. The compounds have been prepared according to the methods of the examples. In the table 3, m represents 1 and o represents 2, (dec.) indicates the decomposition of the compound, (Rot.) indicates the levorotatory or dextrorotatory properties of the enantiomeric compound. R1 R3 R7 R6 N3 R2 z N Y m )o R4 R5 (I) Table 3 No. Rot R2 Z R1 R4 R5 R6 R7 Y R3 n Mp *c salt N 1 (+/-) N N H H H H 0 H 0 286-288 base N I Free 2 (+/) bond N H H H H 0 H 0 202-204 base
HC
WO 2008/078196 PCT/IB2007/004409 68 No. Rot R2 Z R1 R4 R5 R6 R7 Y R3 n Mp C salt BrN (+- ",18 Free 3 (+1-) bond H H H H O H 0 287-289 base 0 FN 4 ( bond N NN H H H H 0 H 0 269-271 Free oo base 5 (+/-) bond N H H H H O H 0 259-261 base 6 (+/-) bond N H H H H 0 H 0 260-262 base A 23-232Free 7 (+-) bond N H H H H 0 H 0 230-232 base N 19-9 Free 8 (+/) e bond H H H H 0 H 0 193-195 base N F I Free 9 (+-) bond H H H H O H 0 2 1 3- 2 15 base N 10 (+-)bond H H H H 0 H 0 284-285 base 11 (/-)bondH H H H H 250252 se 0y N Free 1 (+1-) N bond H H H H 0 H 0 250-252 base N 12 (+) N bond H H H H 0 H ,0 309 3 11 bae bas N N I Free 13 (+)bond H H H H 0 H 0 198-200 base WO 2008/078196 PCT/IB2007/004409 69 No. Rot R2 Z R1 R4 R5 R6 R7 Y R3 n Mp *C salt NI Free 14 (+) bond N H H H H 0 H 0 214-216 base
H
3 C NI Free 15 () bond N H H H H 0 H 0 212-214 base
H
3 C N Free 16 (+/-) bond H H H H 0 H 0 216-218 base N N 1 8-250 Free 17 (+/) bond H H H H 0 H 0 base N IN Free 18 ( bond H H H H O H 0 258-260 base N 19 (+-) bond H H H H 0 H 0 217-219 Free HC bond H H H H O H 0 212-214 base N N 20 (+/-) bond -~ H H H H 0 H bas324 Fe N N AN)A Free 21 bond -~ H H H H 0 H 0 30-30 base N 22 W+-) bond - H H H H 0 H 0 300-32 Free N HC N / 1I1 Free 234 bond y H 0 276-2781 as 24 a+) YKbn H H H H 0 H 02-14base WO 2008/078196 PCT/IB2007/004409 70 No. Rot R2 Z R1 R4 R5 R6 R7 Y R3 n Mp *C salt - N >210 Free 25 (+/-) bond H H H H O H 0 (dec.) base N as Free 26 (+/-) b H H H H O H 0 >125 base OCHN oH N 27 (+/-) bond H H H H 0 H 0 215-217 bsre 28 bnd H H H O H 0 25-255 as~e IN -NN Free 28 (+/-) K-- bond - H H H H 0 H 247-249 base bond e- H H H H 0 H 0 30-33 se IN >3 Free 29 <+ bond H H H H 0 H 0 247-249 base N 24-4 Free 30 (D)onU~ ad H H H H 0 H 0 2-44base IN N Free 31 () I bond H H H H O H 0 301-303 base N CN 2527Free 32 (+) -9 bond H H H H 0 H 0 2 6 2 6 base C>C aI28-4 Free 33 (D)onda H H H H 0 H 0 2840base 9 '>233 Free 34 (-1 bond H H H H 0 H 0O(dec.) base N (+1-) INFree 35 bond H H H H 0 H 0 159-161 base WO 2008/078196 PCT/IB2007/004409 71 No. Rot R2 Z R1 R4 R5 R6 R7 Y R3 n Mp C salt cl N 6 (- Free 36 (+/-) bond H H H H 0 H 0 244-246 base 37 (+/-) bond H H H H 0 H 0 258-260 base NN 38 (+/) N bond N H H H H 0 H 0 279-282 base 25025 Free 39 (+/-) N bond N H H H H 0 H 0250253 base NN 40 (+/) N bond N H H H H 0 H 0 255-258 bae 4 )bond N5 Free 41 (+/-) bond H H H H 0 H 0 264-267 se N' N 42 (+/) bond H H H H 0 H 0 277-281 base 2702 Free 43 +1 bond N H H H H 0 H 0 2054base N 4 (+/) bond H H H H 0 H 0 base I.252254 45 (1- bond H H H H 0 H Frbae N - N>270 Free 46 D+) OndW H H H H O H 0O(dec.) base WO 2008/078196 PCT/IB2007/004409 72 No. Rot R2 Z RI R4 R5 R6 R7 Y R3 n Mp C salt IN r II Free 47 (+N) N bond I H H H H 0 H 0 297-299 base N Free 48 (+/-) bond N H H H H 0 H 0 301-304 se Free 49 (+-) bond N H H H H O H 0 298-301 base 50 (+/) e bond N H H H H 0 H 0 300-302 base 51 )bond N H H H H 0 H 0 287-290 base 5bond -N H H H H 0 H 0 282-285 base 5 ( 1 -N bond H H H H 0 H 0 303-305 base
,CH
3 N 54 +- ' bond N H H H H 0 H 0 282-286 base I N Free 55 (4 F bond N H H H H 0 H 0 271-274 base F 1I Free 56 CH' bond N H H H H 0 H 0 293-296 base N Free D 4 > ond H H H H 0 H 0 12-127 base WO 2008/078196 PCT/IB2007/004409 73 No. Rot R2 Z R1 R4 R5 R6 R7 Y R3 n Mp *C salt N I >288 Free 58 (+/-) bond y H H H H 0 H 0 (dec.) base N 59 (/)bond 1 H H H H O H 0 277-279 Fsre 6 1 ( / )b n yHH O H 0 ( e . b a s e N F2 F re e 2 (+/-) N bond H H H H 0 H 0 base N 63 (/-)bon N H H H 24249 sre 641< bond N H H H H O H 0 270-273 bse ~FF Free 60 (+-) bond N H H H H 0 H 0 25-23 base NN H,247 Free 61 (+-) bond N H H H H O H 0 base FN F IiFree I Free 67 (+-) Ho bnd N H H H H O H 0 251-254 bse 68 (+) bond N H H H H 0 H 0 260-263 bse 65 (1) ~JK ban .- H H H OH 275279base WO 2008/078196 PCT/IB2007/004409 74 No. Rot R2 Z R1 R4 R5 R6 R7 Y R3 n Mp *C salt I Free 69 (+/) bond N H H H H 0 H 0 234-236 base N 70 (+-) bond N H H H H 0 H 0 base N 71 (+/) bond N H H H H 0 H 0 234-237 base N 259-6 Free 72 (+ bond N H H H H 0 H 0 25926 base 73 (+) bond N H H H H O H 0 260-262 Fsre N Free 74 (+ bond N H H CH3 H 0 H 0 261-263 base 75 bond N H H CH 3 H 0 H 0 195-197 bse N Free 76 (+ bond N H H CH 3 H 0 H 0 169-171 base N Free 76 (+/-) N~ bond N H H CH2 3 H 0 H 0 169-171 base N 78 (+/ bond H H CH 3 H 0 H 0 180-182 base 79 bond H H CH3 H O H 0 213-215 Free .. CHe 80 (+ ) " bond N H H CH 3 H 0 H 0 194-196 ase Nas WO 2008/078196 PCT/IB2007/004409 75 No. Rot R2 Z RI R4 R5 R6 R7 Y R3 n Mp * salt N 81 bond N H H CH 3 H 0 H 0 193-195 Free N F 140 Free 82 (+/-) bond /N H H CH 3 H 0 H 0 (dec.) base N Free 83 (+ bond N H H CH 3 H 0 H 0 179-181 base N 2 Free 84 (+1) bond ~ N H H OH 3 H 0 H 0 2921base 85 (+ bond N H H CH3 H O H 0 212-214 bae H,CO NN Free 85 (+/-) I bond ~ N H H OH 3 H 0 H 0 212-214 base H CC' N 86 (+ bond H H CH 3 H 0 H 0 217-219 Free
H
3
C
0 base CI N~ " Free 87 (+/) F F bond H H CH 3 H 0 H 0 231-233 base 88 )bond H H OH 3 H 0 H 0 318-320 be S<121-0 Free 89 (+) .< bond -N H H OH 3 H 0 H 0 2103base BrN22-26Fe 90 'Y",I bond ~ N H H OH 3 H 0 H 0 2426base N Free 91 (1 i bond ~ N H H OH 3 H 0 H 0 250-252 bs F F WO 2008/078196 PCT/IB2007/004409 76 No. Rot R2 Z R1 R4 R5 R6 R7 Y R3 n Mp C salt N 1113 Free 92 (+/-) C CHO bond H H CH 3 H 0 H 0 171-173 base 9N NN 94 bond N H H OH 2
CH
3 H 0 H 0 200-20 e N 95 bond N H H CH 3 H 0 H 0 205-207 Free A.1) base SH Ni Free 9 (+/) bond N H H CH 3 H 0 H 0 198-200 ase Free 96 (+/) bond N H H CH 2
CH
3 H 0 H 0 296-299 base IC H 3 N 21I1 Free 99 (+/) bond N H H CH 2
CH
3 H 0 H 0 1-14base N F Fe 98 (+) /bond -N H H CH 2
CH
3 H 0 H 0 204-206 bae Cbas 0 < >, b o n d FH H rHe H B1 9 -1 9 2 F e ~ (+) ~ bon ~N H H 2 Ca H 0 H 0 14- base K]9019 Free 100 (+)NC~ bond ~N H H H H 0 Br 01-92base WO 2008/078196 PCT/IB2007/004409 77 No. Rot R2 Z RI R4 R5 R6 R7 Y R3 n Mp *C salt Cl N N Free 101 (+) bond N H H CH 2
CH
3 H 0 H 0 194-196 base Free 102 bond N H H H H 0 H 0 199-200 base 20020 Free 103 () H bond N H H H H 0 H 0 200-202 base CH, NNi Free 104 (+) bond N H H CH 3 H 0 H 0 109-111 base Free I5 114 base 105 bond H H CH 3 H 0 H 0 (dec) N CGH 111 Free 106(~) NN bond N H H CH 3 H H O(dec) base , 8 Free 107 (+) H '- bond N H H CH 3 H 0 H 0 base 126 Free 108 (~ bond N H H CH 3 H 0 H 0 (dec) base 109 (+) bond N H H CH 3 H 0 H 0 176-178 bsre Test Example: Inhibitory activity of the medicament of the present invention against GSK3P: Two different protocols can be used.
WO 2008/078196 PCT/IB2007/004409 78 In a first protocol : 7.5 pM of prephosphorylated GS1 peptide and 10 pM ATP (containing 300,000 cpm of 33 P-ATP) were incubated in 25 mM Tris-HCI, pH 7.5, 0.6 mM DTT, 6 mM MgC 2 , 0.6 mM EGTA, 0.05 mg/mI BSA buffer for 1 hour at room temperature in the presence of GSK3beta (total reaction volume : 100 microliters). In a second protocol : 4.1 pM of prephosphorylated GS1 peptide and 42 pM ATP (containing 260,000 cpm 33 P-ATP) were incubated in 80 mM Mes-NaOH, pH 6.5, 1 mM Mg acetate, 0.5 mM EGTA, 5 mM 2-mercaptoethanol, 0.02% Tween 20, 10% glycerol buffer for 2 hours at room temperature in the presence of GSK3beta. Inhibitors were solubilised in DMSO (final solvent concentration in the reaction medium, 1%). The reaction was stopped with 100 microliters of a solution made of 25 g polyphosphoric acid (85% P 2 0 5 ), 126 ml 85% H 3
PO
4 , H 2 0 to 500 ml and then diluted to 1:100 before use. An aliquot of the reaction mixture was then transferred to Whatman P81 cation exchange filters and rinsed with the solution described above. Incorporated 33 P radioactivity was determined by liquid scintillation spectrometry. The phosphorylated GS-1 peptide had the following sequence: NH2-YRRAAVPPSPSLSRHSSPHQS(P)EDEE-COOH.(Woodgett, J. R. (1989) Analytical Biochemistry 180, 237-241. The GSK3p inhibitory activity of the compounds of the present invention are expressed in IC50, and as an illustration the range of IC5o's of the compounds in table 1 is between 0,01 nanomolar to 3 micromolar concentrations. For example compound No. 13 of table 1 shows an IC5o of 0.014 pM, compound 14 of table 2 shows an IC50 of 0.004 pM and compound 53 of table 3 shows an IC50 of 0.005 pM. Formulation Example (1) Tablets The ingredients below were mixed by an ordinary method and compressed by using a conventional apparatus. Compound of Example 1 30 mg Crystalline cellulose 60 mg Corn starch 100 mg WO 2008/078196 PCT/IB2007/004409 79 Lactose 200 mg Magnesium stearate 4 mg (2) Soft capsules The ingredients below were mixed by an ordinary method and filled in soft capsules. Compound of Example 1 30 mg Olive oil 300 mg Lecithin 20 mg (1) Parenteral preparations The ingredients below were mixed by an ordinary method to prepare injections contained in a 1 ml ampoule. Compound of Example 1 3 mg Sodium chloride 4 mg Distilled water for injection 1 ml Industrial Applicability The compounds of the present invention have GSK3p inhibitory activity and are useful as an active ingredient of a medicament for preventive and/or therapeutic treatment of diseases caused by abnormal activity of GSK3p and more particularly of neurodegenerative diseases.

权利要求:
Claims (13)
[1] 1. A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: R1 R7 R6 N R3 1z N N 0 Ym )o R4 R5 (I) wherein: Y represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C 1 - 2 alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a C 1 . 6 alkyl group, a hydroxyl group, a C 1 . 6 alkoxy group, a C 1 - 2 perhalogenated alkyl group or an amino group; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted by a C 1 .e alkyl group, a C 1 . 6 alkoxy group or a halogen atom; R2 represents a 4-15 membered heterocyclic group, this group being optionally substituted by 1 to 4 substituents selected from a C 1 . 6 alkyl group, a halogen atom, a C 1 - 2 perhalogenated alkyl group, a C 1 - halogenated alkyl group, a hydroxyl group, a C1. 6 alkoxy group, a C1-2 perhalogenated alkoxy group, a C1_6 halogenated alkoxy group, a nitro, a cyano, an amino, a C 1 . 6 monoalkylamino group, a C 2 - 12 dialkylamino group, a S-(C 1 . 6 -alkyl) group, an 4-15 membered heterocyclic group, an aryl group, a O-aryl group or a S-aryl group, the above mentioned groups being optionally substituted by 1 to 4 substituents selected from a C 1 .6 alkyl group, a halogen atom, a (C 1 .- ) alkoxy group, a C(0)0 (C 1 . 6 -alkyl) or a C(0)0 (aryl) group; R3 represents a hydrogen atom, a C 1 . 6 alkyl group or a halogen atom; R4 and R5 represent, each independently, a hydrogen atom, a C 1 . 6 alkyl group, optionally substituted by 1 to 4 substituents selected from a halogen atom, a phenyl group, a hydroxyl group or a C 1 .3 alkoxy group; R6 represents a hydrogen atom, a C 1 . 6 alkyl group optionally substituted by a halogen atom or a cycloalkyl group, or a halogen atom; WO 2008/078196 PCT/IB2007/004409 81 R7 represents a hydrogen atom or a C 1 . 6 alkyl group; n represents 0 to 3; m represents 0 to 1; o represents 0 to 2; in the form of a free base or of an addition salt with an acid.
[2] 2. A pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1, wherein R1 represents an unsubstituted
[3] 4-pyridine ring or unsubstituted 4-pyrimidine ring, in the form of a free base or of an addition salt with an acid. 3. A pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1, wherein R2 represents a benzotriazole group, quinoxaline group, benzodioxepine group, benzodioxane group, benzodioxine group, benzodioxole group, indole group, pyridine group, pyrindine group, quinoline group, pyridazine group, isoquinoline group, pyrimidine group, naphthyridine group, imidazopyridine group, cinnoline group or benzofuran group and where the above-mentioned group being optionally substituted by 1 to 4 substituents selected from a C1.6 alkyl group, a halogen atom, a C1.6 alkoxy group, a C 1 - 2 perhalogenated alkoxy group, an amino, a S-C 1 . 6 -alkyl group, a furan group, a thiophene group, a [1,4]diazepane, a phenyl group, a O-phenyl group or a S-phenyl group, the above-mentioned groups being optionally substituted by 1 to 4 substituents selected from a C1-6 alkyl group, a halogen atom, a C 1 . 6 alkoxy group, or a C(0)0 C 1 . 6 -alkyl in the form of a free base or of an addition salt with an acid. 4. A pyrimidone derivative or a salt thereof, or a solvate thereof or a hydrate thereof according to claim 1, wherein R4 and R5 represent a hydrogen atom; (m+o) represents 2 or 3; R2 represents a benzotriazole group, quinoxaline group, benzodioxepine group, benzodioxane group, benzodioxine group, benzodioxole group, indole group, pyridine group, pyrindine group, quinoline group, pyridazine group, isoquinoline group, pyrimidine group, naphthyridine group, imidazopyridine group, cinnoline group or benzofuran group and where the above-mentioned group being optionally substituted by 1 to 4 substituents selected from a C1.6 alkyl group, a halogen atom, a Coe alkoxy group, a C1-2 perhalogenated alkoxy group, an amino, a S-C 1 . 6 -alkyl group, a furan group, a thiophene group, a [1,4]diazepane, a phenyl group, a 0-phenyl group or a S-phenyl group, the above-mentioned groups being optionally substituted by 1 to 4 substituents selected from a C1.6 alkyl WO 2008/078196 PCT/IB2007/004409 82 group, a halogen atom, a C1 alkoxy group, or a C(0)O C 1 . 6 -alkyl; R6 represents a hydrogen atom, a methyl or an ethyl group; n represents 0; Z represents a bond, and Y represents an oxygen atom, in the form of a free base or of an addition salt with an acid.
[4] 5. A pyrimidone derivative which is selected from the group consisting of: * (+/-) 2,2-Dimethyl-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2 pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide * (+/-) 1-Methyl-1 H-benzotriazole-5-carboxylic acid (4-oxo-2-pyridin-4-yl 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide * (+/-) Quinoxaline-6-carboxylic acid (4-oxo-2-pyridin-4-yl-6,7,8,9-tetrahydro 4H-pyrido[1,2-a]pyrimidin-9-yl)-amide * (+/-) 2,3-Dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyrimidin-4-yl 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide * (+/-)2,2-Difluoro-benzo[1,3]dioxole-4-carboxylic acid (4-oxo-2-pyridin-4-yl 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yI)-amide * (+/-) 3,4-Dihydro-2H-benzo[b][1,4]dioxepine-6-carboxylic acid (4-oxo-2 pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide * (+/-) Benzofuran-2-carboxylic acid (4-oxo-2-pyridin-4-yl-6,7,8,9-tetrahydro 4H-pyrido[1,2-a]pyrimidin-9-yl)-amide * (+/-) 2,2-Dimethyl-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2 pyrimidin-4-yI-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide * (+/-) 8-Amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid (4 oxo-2-pyrimidin-4-yl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl) amide * (+/-) 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (4-oxo-2-pyrimidin-4- WO 2008/078196 PCT/1B2007/004409 83 yI -6,7 ,8, 9-tetra hyd ro-4 H-pyrid o[1, ,2-a]pyri mid in-9-yI)-a mide *(+/-) 6-Fluoro-4H-benzo[1 ,3]dioxine-8-carboxylic acid (4-oxo-2-pyridin-4-yI 6,7,8 ,9-tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide *(-)2 ,3-Dihydro-benzofuran-5-carboxylic acid (4-oxo-2-pyridin-4-yI-6,7,8 ,9 tetra hyd ro-4 H-pyridol 1,2-a]pyrim id in-9-yi)-amide *(+/-) 8-Amino-7-chloro-2 ,3-dihydro-benzo[1 ,4]dioxine-5-carboxylic acid (4 oxo-2-pyridin-4-yI-6,7,8,9-tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide *(+/-) 1-Methyl-i H-indole-3-carboxylic acid (4-oxo-2-py rid in -4-yi-6,7, 8,9 tetrahyd ro-4H-pyrido[1 ,2-a]pyrimid in-9-yI)-amide * (+1-)2-Methoxy-N-(4-oxo-2-pyridin-4-yI-6,7,8,9-tetrahydro-4H-pyrido[1 ,2 alpyrimidin-9-yI)-n icotinamide *(+/-) 6,7-Dihydro-5H-I1 Ipyrind ine-6-carboxylic acid (4-oxo-2-py rid in-4-yl 6,7 ,8,9-tetrahydro-4H-pyridoll ,2-a]pyrimidin-9-yI)-amide *(1)2-Methoxy-N-(4-oxo-2-pyrimid in-4-yI-6 ,7,8 ,9-tetrahydro-4H-pyrido[l ,2 a]pyrimidin-9-yi)-nicotinamide *(+/-) 2 ,6- Dimeth oxy-N-(4-oxo-2-py rim id in-4-yI-6,7,8,9-tetra hyd ro-4H pyrido[1 ,2-a]pyrimidin-9-yI)-nicotinamide *(+/-) N -(4-Oxo-2-py rim id in-4-yi-6 ,7,8 ,9-tetra hyd ro -4 H-py rid o[l ,2 a]py rim id in-9-yI)-6-(2,2,2-trifl u oro-eth oxy)-n icoti nam ide *(+/-) 2-Fluoro-N-(4-oxo-2-pyrimidin-4-yI-6,7 ,8,9-tetrahydro-4H-pyrido[1 ,2 a]pyrimidin-9-yi)-nicotinamide *(+/-) N-(4-Oxo-2-pyrimid in-4-yl-6 ,7,8 ,9-tetrahydro-4H-pyrido[1 2 a ]py rim id in-9-yI)-2-p-to lyloxy-n icoti namid e *(+/-) 2-(4-C h I oro-p he noxy)-N -(4-oxo-2-pyri mid in -4-yI-6,7 ,8 ,9-tetra hyd ro-4 H pyrido[1 ,2-alpyrimidin-9-yI)-nicotinamide WO 2008/078196 PCT/1B2007/004409 84 * (+1-) 2-Methylsulfanyl-N-(4-oxo-2-pyrimidin-4-yI-6,7, 8,9-tetrahydro-4H pyridoll ,2-a]pyrimidin-9-yI)-nicotinamide *(+/-) 5-Furan-2-yI-N-(4-oxo-2-pyrimidin-4-yI-6,7,8 ,9-tetrahydro-4H pyridoji ,2-a]pyrimidin-9-yI)-nicotinamide *(+/-) 5-(2-Methoxy-phenyl)-N-(4-oxo-2-pyrimidin-4-yI-6,7, 8,9-tetrahydro-4H pyridol,2-a]pyrimidin-9-yI)-nicotinamide *(+/-) 5-(3,4-Dimethoxy-phenyl)-N-(4-oxo-2-pyrimidin-4-yI-6,7,8 ,9-tetrahydro 4H-pyrido[1 ,2-a]pyrimidin-9-yI)-n icotinamide *(+/-) Quinoline-3-carboxylic acid (4-oxo-2-pyrimidin-4-yI-6,7 ,8,9-tetrahydro 4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide *(+/-) N -(4-Qxo-2-py rim id in-4-yi-6 ,7 ,8,9-tetrahyd ro-4 H-pyrid o[ 1,2 a]pyrimidin-9-yI)-6-th iophen-2-yI-nicotinamide *(+/-) 4-[5-(4-Oxo-2-py rim id in-4-yI1-6,7 ,8 ,9-tetrahyd ro-4 H-py rid o[l ,2 a]pyrimidin-9-ylcarbamoyl)-pyridin-2-y]-[1 ,4]diazepane-1 -carboxylic acid tert-butyl ester *(+/-) 6-M ethyl- N-(4-oxo-2-py rim id in-4-yi-6,7 ,8,9-tetra hyd ro-4H -py rido [1, 2 a]pyrimidin-9-yl)-nicotinamide *(+/-) N-(4-Oxo-2-pyrimidin-4-yI-6 ,7,8,9-tetrahyd ro-4H-pyrido[1 ,2 a]pyrimidin-9-yI)-2-propylsulfanyl-nicotinamide *(+/-) N-(4-Oxo-2-pyrimidin-4-yI-6 ,7 ,8,9-tetrahyd ro-4H-pyrido[1 ,2 alpyrimid in-9-yI)-nicotinamide * (+1-)6-Chloro-N-(4-oxo-2-pyrimidin-4-yl-6,7 ,8 ,9-tetrahydro-4H-pyrido[1 ,2 a]pyrimidin-9-yI)-nicotinamide *(+/-) 2-Methoxy-N-(9-methyl-4-oxo-2-pyrimid in-4-yI-6 ,7 ,8, 9-tetrahyd ro-4H pyrido[1 ,2-a]pyrimidin-9-yI)-nicotinamide *(1)4-Methoxy-pyrid ine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI-6,7,8,9- WO 2008/078196 PCT/1B2007/004409 85 tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide *(+/-) 3,6-Dimethoxy-pyridazine-4-carboxylic acid (4-oxo-2-pyrimidin-4-yi 6,7,8, 9-tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide *(+/-) Pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI-6,7, 8, 9-tetrahydro 4H-pyrido 1 ,2-a]pyrimidin-9-yI)-amide *(+/-) 6-Methoxy-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI-6,7,8, 9 tetra hyd ro-4 H-pyrido[ 1,2-a]pyrim id in-9-yI)-am ide *(-)4-Methoxy-quinoline-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI-6,7,8 ,9 tetra hyd ro-4 H-pyrido[1, ,2-a]pyrim id in-9-yI)-am ide *(+/-) Isoquinoline-1 -carboxylic acid (4-oxo-2-pyrimidin-4-yI-6,7,8,9 tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide *(+/-) 5-Chloro-2-methylsulfanyl-pyrimidine-4-carboxylic acid (9-methyl-4 oxo-2-pyri mid in-4-yI-6,7,8,9-tetrahyd ro-4 H-py rid o[1, ,2-alpyri mid in-9-yI) amide *(+/-) [1 ,6]Naphthyridine-5-carboxylic acid (4-oxo-2-py rim id in-4-yI1-6,7 ,8 ,9 tetrahyd ro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide *(+/-) 6-Chloro-pyrid ine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI-6 ,7,8 ,9 tetra hyd ro-4 H-pyrido[1 ,2-a]pyrimid in-9-yI)-am ide *(+/-) [1 ,5]Naphthyridirie-2-carboxylic acid (4-oxo-2-pyrimid in-4-yi-6 ,7,8,9 tetra hyd ro-4 H-pyrido[ 1,2-a]pyrimidin-9-yI)-am ide *(+/-) 6-(2,6-Dimethoxy-phenyl)-pyridine-2-carboxylic acid (4-oxo-2 pyrimidin-4-yI-6,7 ,8 ,9-tetrahydro-4H-pyrido[ 1,2-a]pyrimidin-9-yI)-amide *(+/-) 6-(2-F Iuoro-phenyl)-pyrid ine-2-carboxylic acid (4-oxo-2-pyrim id in-4-yi 6,7 ,8,9-tetrahydro-4H-pyrido[1 ,2-ajpyrimidin-9-yI)-amide *(1)8-Amino-7-chloro-2,3-dihydro-benzo[1 ,4]dioxine-5-carboxylic acid (9 methyl-4-oxo-2-pyrim id in -4-yI-6,7,8,9-tetra hyd ro-4 H-pyrido [1, ,2-a] pyri mid in- WO 2008/078196 PCT/1B2007/004409 86
[5] 9-yI)-amide *(+/-) 3,6-Dimethoxy-pyridazine-4-carboxylic acid (9-methyl-4-oxo-2 pyri mid in -4-yI-6,7, 8, 9-tetrahyd ro-4 H-pyrid o[1, ,2-a]py rim id in-9-y I)-am ide *(+/-) 2 ,2-Dimethyl-2 ,3-dihydro-benzofuran-7-carboxylic acid (9-methyl-4 oxo-2-pyri mid in -4-yi-6,7,8,9-tetrahyd ro-4 H-py rid o[1, ,2-alpyrim id in-9-y I) amide *(+/-) 6-Fluoro-4H-benzo[1 ,3]dioxine-8-carboxylic acid (9-methyl-4-oxo-2 pyrimidin-4-yI-6,7,8, 9-tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide *(+/-) [1 ,5]Naphthyridine-2-carboxylic acid (9-methyl-4-oxo-2-pyrimid in-4-yI 6 ,7,8,9-tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide *(1)2 ,3-Dihydro-benzofuran-7-carboxylic acid (9-methyl-4-oxo-2-pyrimidin 4-yI-6,7,8 ,9-tetrahyd ro-4H-pyrido[1 ,2-a]pyrimid in-9-yI)-amide *(-)Pyridine-2-carboxylic acid (9-methyl-4-oxo-2-pyrimid in-4-yI-6 ,7,8 ,9 tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide *(+/-) 6-Chloro-pyridine-2-carboxylic acid (9-methyl-4-oxo-2-pyrimidin-4-yI 6 ,7,8,9-tetrahydro-4H-pyrido[1 ,2-a]pyrimid in-9-yI)-amide *(+/-) [1 ,6]Naphthyridine-5-carboxylic acid (9-methyl-4-oxo-2-pyrimidin-4-yI 6 ,7,8,9-tetrahydro-4H-pyrido[1 ,2-a]pyrimid in-9-yI)-amide *(+/-) N-(9-Methyl-4-oxo-2-pyrimidin-4-yi-6 .7,8,9-tetrahyd ro-4H-pyrido[1 2 a]pyrimidin-9-yi)-nicotinamide *(+/-) 5-Bromo-benzofuran-2-carboxylic acid (9-methyl-4-oxo-2-pyrimidin-4 yI-6,7,8 ,9-tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide *()6-(2-F lu oro-p he nyl)-py rid ine-2-ca rboxyl ic acid (4-oxo-2-pyrimidin-4-yl 6,7,8 ,9-tetrahydro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide *(-) 6-(2-Fluoro-phenyl)-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI 6,7,8, 9-tetrahyd ro-4H-pyrido[1 ,2-a]pyrimidin-9-yI)-amide WO 2008/078196 PCT/IB2007/004409 87 * (+) 2-Methoxy-N-(9-methyl-4-oxo-2-pyrimidin-4-yI-6,7,8,9-tetrahydro-4H pyrido[1,2-a]pyrimidin-9-yl)-nicotinamide * (-) 2-Methoxy-N-(9-methyl-4-oxo-2-pyrimidin-4-yi-6,7,8,9-tetrahydro-4H pyrido[1,2-a]pyrimidin-9-yl)-nicotinamide * (+) [1,5]Naphthyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl-6,7,8,9 tetrahydro-4H-pyrido[l,2-a]pyrimidin-9-yl)-amide * (-) [1,5]Naphthyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl-6,7,8,9 tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl)-amide * (+/-) 2,2-Dimethyl-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2 pyridin-4-yI-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidin-8-yl)-amide * (+/-) 1-Methyl-iH-benzotriazole-5-carboxylic acid (4-oxo-2-pyrid in-4-yI 4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidin-8-yl)-amide * (+/-) 8-Amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid (4 oxo-2-pyridin-4-yl-4,6,7,8-tetrahydro-pyrrolo[1 ,2-a]pyrimidin-8-yl)-amide * (+/-) 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (4-oxo-2-pyridin-4-yl 4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidin-8-yl)-amide * (+/-) Quinoxaline-6-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6,7,8-tetrahyd ro pyrrolo[1,2-a]pyrimidin-8-yl)-amide * (+/-) 2,3-Dihydro-benzofuran-5-carboxylic acid (4-oxo-2-pyridin-4-yi-4,6,7,8 tetrahydro-pyrrolo[1,2-a]pyrimidin-8-yl)-amide * (+/-) 1-Methyl-1H-indole-3-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6,7,8 tetrahydro-pyrrolo[ 1,2-a]pyrimidin-8-yl)-amide * (+/-) 5-Bromo-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyridin-4 yl-4,6,7,8-tetrahyd ro-pyrrolo[1,2-a]pyrimidin-8-yl)-amide * (+/-) -2,3-Dihydro-benzofuran-2-carboxylic acid (4-oxo-2-pyridin-4-yl- WO 2008/078196 PCT/1B2007/004409 88 4,6,7,8-tetrahydro-pyrrolo[1 ,2-a]pyrimidin-8-yI)-amide *(+/-) 6,7-Dihydro-5H-[1 ]pyrindine-6-carboxylic acid (4-oxo-2-pyridin-4-yi 4,6,7, 8-tetrahydro-pyrrolo[1 ,2-a]pyrimidin-8-yI)-amide *(+1-) Benzofuran-2-carboxylic acid (4-oxo-2-pyridin-4-yI-4,6,7, 8-tetrahydro pyrrolo[1 ,2-a]pyrimidin-8-yI)-amide *(+/-) [1, 5]Naphthyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI-4,6,7,8 tetra hyd ro-pyrrolo[ 1,2-a]pyrim id in-8-yI)-amide *(+/-) 2-Methoxy-N-(4-oxo-2-pyrimidin-4-yI-4 ,6,7 ,8-tetrahydro-pyrrolo[1 ,2 ajpyrimidin-8-yi)-nicotinamide * (1-)5-Chloro-2-methylsulfanyl-pyrimidine-4-carboxylic acid (4-oxo-2 pyrimidin-4-yI-4,6,7, 8-tetrahyd ro-pyrrololl ,2-a]pyrimidin-8-yI)-amide * (1-) Isoqu inoline-1 -carboxylic acid (4-oxo-2-pyrimidin-4-yI-4,6,7 ,8 tetrahyd ro-pyrrolo[1 ,2-a]pyrimidin-8-yI)-amide *(+1-) 2-Methoxy-N-(4-oxo-2-pyridin-4-yI-4 ,6,7,8-tetrahyd ro-pyrrolo[1 ,2 a]pyrimidin-8-yI)-nicotinamide * (1-)5-Chloro-2-methylsulfanyl-pyrimidine-4-carboxylic acid (4-oxo-2 pyridin-4-yI-4 ,6,7 ,8-tetrahydro-pyrrolo[1 ,2-alpyrimidin-8-yI)-amide *(+/-) Isoquinoline-1 -carboxylic acid (4-oxo-2-py rid in-4-yi-4,6,7 ,8-tetra hyd ro pyrrololl ,2-a~pyrimidin-8-yI)-amide *(+/-) Pyrid ine-2-carboxylic acid (4-oxo-2-py rim id i n-4-yI-4 ,6,7 ,8-tetra hyd ro pyrrolof I,2-a]pyrimidin-8-yI)-amide *(+/-) 6-Chloro-pyridine-2-carboxylic acid (4-oxo-2-pyridin-4-yI-4,6 ,7 ,8 tetra hyd ro-pyrrolo[1, ,2-alpyri mid in-8-yI)-am ide * (1-)[1 ,5]Naphthyridine-2-carboxylic acid (4-oxo-2-pyridin-4-yI-4 ,6,7,8 tetrahydro-pyrrolo[1 ,2-a]pyrimidin-8-yI)-amide WO 2008/078196 PCT/IB2007/004409 89 * (+/-) 8-Amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid (4 oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl) amide * (+/-) 2-Methoxy-N-(4-oxo-2-pyrimidin-4-yI-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-y)-nicotinamide * (+/-) 5-Bromo-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyrimidin 4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (4-oxo-2-pyrimidin-4 yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 O-yl)-amide * (+/-) 5-Chloro-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyrimidin 4-yl-4,6, 7 ,8,9,10-hexahydro-pyrimido[1,2-a]azepin-1 O-yl)-amide * (+/-) 2,3-Dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) 2,2-Dimethyl-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2 pyrimidin-4-yi-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 O-yl)-amide * (+/-) 2,2-Dimethyl-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2 pyridin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (4-oxo-2-pyridin-4-yi 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) 5-Chloro-2,3-dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyridin-4 yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) 2,3-Dihydro-benzofuran-7-carboxylic acid (4-oxo-2-pyridin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 O-yl)-amide * (+/-) 8-Amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid (4 oxo-2-pyridin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl) amide * (+/-) 2-Methoxy-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9 ,10-hexahydro- WO 2008/078196 PCT/IB2007/004409 90 pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide N () 2-Methoxy-N-(4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-y)-nicotinamide * (-) 2-Methoxy-N-(4-oxo-2-pyrimidin-4-yi-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide * (+/-) 2,6-Dimethoxy-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide * (+/-) N-(4-Oxo-2-pyridin-4-yI-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin 1 0-yl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide * (+/-) 2-Fluoro-N-(4-oxo-2-pyridin-4-yI-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-y)-nicotinamide * (+/-) 2-Methylsulfanyl-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-y)-nicotinamide * (+/-) N-(4-Oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin 1 0-yl)-2-p-tolyloxy-nicotinamide * (+/-) 2-(4-Chloro-phenoxy)-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide * (+/-) 3H-imidazo[4,5-b]pyridine-6-carboxylic acid (4-oxo-2-pyridin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) N-(4-Oxo-2-pyridin-4-yI-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin I 0-yl)-6-thiophen-2-yI-nicotinamide * (+/-) 6-Methyl-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-yl)-nicotinamide * (+/-) 5-Furan-2-yl-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,
[6] 10-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide WO 2008/078196 PCT/IB2007/004409 91 * (+/-) 5-(2-Methoxy-phenyl)-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide * (+/-) 5-(3,4-Dimethoxy-phenyl)-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide * (+/-) Quinoline-3-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) 4-[5-(4-Oxo-2-pyridin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2 a]azepin-1 0-ylcarbamoyl)-pyridin-2-yl]-[1,4]d iazepane- 1 -carboxylic acid tert-butyl ester * (+/-) 5-(4-Bromo-phenyl)-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide * (+/-) N-(4-Oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin 10-yl)-nicotinamide * (+/-) 6-Chloro-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-yl)-nicotinamide * (+/-) 2-Chloro-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2 a]azepin-1 0-yi)-nicotinamide * (+/-) N-(4-Oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin 1 0-yI)-2-phenylsulfanyl-nicotinamide * (+/-) N-(4-Oxo-2-pyridin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin 10-yl)-2-propylsulfanyl-nicotinamide * (+/-) 2-(4-Chloro-phenylsulfanyl)-N-(4-oxo-2-pyridin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide * (+/-) 4-Methyl-2-phenyl-pyrimidine-5-carboxylic acid (4-oxo-2-pyrimidin-4 yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) Pyrimidine-5-carboxylic acid (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10- WO 2008/078196 PCT/IB2007/004409 92 hexahydro-pyrimido[1,2-a]azepin-1 O-yl)-amide * (+/-) 5-Chloro-2-methylsulfanyl-pyrimidine-4-carboxylic acid (4-oxo-2 pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) Pyridazine-4-carboxylic acid (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) 6-Phenyl-pyrimidine-4-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) Cinnoline-4-carboxylic acid (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) 3,6-Dimethoxy-pyridazine-4-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) Isoquinoline-1-carboxylic acid (4-oxo-2-pyridin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) 3-Phenyl-cinnoline-4-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) [1,6]Naphthyridine-5-carboxylic acid (4-oxo-2-pyridin-4-yI-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) [1,5]Naphthyridine-2-carboxylic acid (4-oxo-2-pyridin-4-yI-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) [1,6]Naphthyridine-5-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) [1,5]Naphthyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) 4-Methoxy-quinoline-2-carboxylic acid (4-oxo-2-pyrimidin-4-yi 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) Isoquinoline-1-carboxylic acid (4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10- WO 2008/078196 PCT/1B2007/004409 93 hexahydro-pyrimido[1 ,2-a]azepin-1 O-y)-amide *(+/-) Pyridine-2-carboxylic acid (4-oxo-2-pyrimid in-4-yI-4 ,6,7,8, 9,1 0 hexahydro-pyrimido[1 ,2-alazepin-1 O-yI)-amide *(+/-) 6-Chloro-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI 4,6,7,8,9,1 0-hexahydro-pyrimido[1 ,2-a]azepin-1 0-yI)-amide *(+/-) 4-Methoxy-pyrid ine-2-carboxyl ic acid (4-oxo-2-pyrim id in-4-yI 4,6,7,8,9,1 O-hexahydro-pyrimido[1 ,2-a]azepin-1 O-y)-amide *(+/-) 3, 5-Difluoro-pyrid ine-2-carboxylic acid (4-oxo-2-pyrimid in-4-yI 4,6,7,8,9,1 0-hexahydro-pyrimido[1 ,2-a]azepin-1 0-yI)-amide *(+/-) 6-(2,6-D imeth oxy-phe nyl)-py rid ine-2-carboxyl ic acid (4-oxo-2 pyrimidin-4-yI-4,6,7 ,8,9, 1 0-hexahydro-pyrimido[1 ,2-a]azepin-1 0-yI)-amide *(+/-) 4-Methyl-2-phenyl-pyrimidine-5-carboxylic acid (4-oxo-2-pyridin-4-yI 4,6,7,8,9, 1 Q-hexahydro-pyrimido[1 ,2-a]azepin-1 O-yI)-amide *(+/-) 3-Phenyl-cinnoline-4-carboxylic acid (4-oxo-2-pyridin-4-yI-4 ,6,7, 8,9,10 hexahydro-pyrimido[1 ,2-a]azepin-1 0-yI)-amide * (1-)3,6-Dimethoxy-pyridazine-4-carboxylic acid (4-oxo-2-pyridin-4-yi 4,6,7,8,9, 1 0-hexahydro- pyrimidofl ,2-alazepin-1 0-yI)-amide *(+/-) 2-Methyl-4-phenyl-pyrimidine-5-carboxylic acid (4-oxo-2-pyridin-4-yi 4,6,7,8,9,1 0-hexahyd ro-pyrimido[1 ,2-a]azepin-1 0-yI)-amide *(+/-) 6-Phenyl-pyrimidine-4-carboxylic acid (4-oxo-2-pyridin-4-yI 4,6,7,8,9,1 0-hexahydro-pyrimido[1 ,2-a]azepin-1 0-yI)-amide *(+/-) 6-(2-Fluoro-phenyl)-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI 4,6,7,8,9, 1 0-hexahyd ro-pyrimido[1 ,2-a]azepin-1 0-yI)-amide *(+/-) 2,6-Dimethoxy-N-(4-oxo-2-pyrimidin-4-y-4 ,6,7,8,9,1 0-hexahyd ro pyrimidoll ,2-ajazepin-1 0-yI)-nicotinamide WO 2008/078196 PCT/1B2007/004409 94 * (+1-) N-(4-Oxo-2-pyrimidin-4-yI-4 ,6,7,8, 9,1 O-hexahydro-pyrimido[1 ,2 alazepin-l O-yI)-6-(2 ,2,2-trifluoro-ethoxy)-nicotinamide *(+1-) 2- FlIu oro-N-(4-oxo-2-py rim id in-4-yI1-4,6,7,8,9,1 0-hexahydro pyrimidoll ,2-ajazepin-1 O-yi)-nicotinamide *(+1-) 6-F ura n-2-yI-N-(4-oxo-2-py rim id in-4-yI1-4 ,6,7,8,9,1 0-hexahyd ro pyrimidoll ,2-ajazepin-1 O-y)-nicotinamide *(+/-) 6-Methoxy-pyridine-2-carboxylic acid (4-oxo-2-pyrimidin-4-yI 4,6,7,8,9, 1 O-hexahydro-pyrimido[1 ,2-a]azepin-1 O-yI)-amide *(+/-) Quinoline-3-carboxylic acid (4-oxo-2-pyrimidin-4-yI-4,6,7,8,9, 10 hexahydro-pyrimido[1 ,2-a]azepin-1 0-yI)-amide *(+1-) 4-[5-(4-Oxo-2-pyrimidin-4-yI-4,6,7, 8,9,1 0-hexahydro-pyrimidofl ,2 a]azepin-1 O-ylca rbamoyl)-py rid in-2-y]-[ 1 ,4]d iazepa ne-1 -carboxylic acid tert-butyl ester *(+1-) 5-(2-Methoxy-phenyl)-N-(4-oxo-2-pyrimid in-4-yI-4 ,6,7,8, 9,1 0 hexahydro-pyrimido[1 ,2-a]azepin-1 O-yI)-n icotinamide * (+1-) 5-(3,4-Dimethoxy-phenyl)-N-(4-oxo-2-pyrimidin-4-yI-4,6,7,8,9, 10 hexahyd ro-pyrimido[1 ,2-alazepin-1 0-yI)-nicotinamide *(+/-) 2,6-Dimethoxy-pyrimidine-4-carboxylic acid (4-oxo-2-pyrimidin-4-yI 4,6,7,8,9,1 O-hexahydro-pyrimido[1 ,2-a]azepin-1 0-yI)-amide *(+/-) 5-B romo-2-methylsulIfanyl-py rim id ine-4-ca rboxyl ic acid (4-oxo-2 pyrimidin-4-yI-4,6,7,8,9, 1 0-hexahydro-pyrimido[1 ,2-a]azepin-1 0-yI)-amide *(+/-) [1,5]Naphthyridine-2-carboxylic acid (1 0-methyl-4-oxo-2-pyrimidin-4 yI-4,6,7,8,9, I 0-hexahydro-pyrimido[1 ,2-a]azepin-1 0-yI)-amide *(+/-) 6-Methoxy-pyridine-2-carboxylic acid (1 0-methyl-4-oxo-2-pyri mid in-4 yI-4,6,7,8,9, 1 0-hexahydro-pyrimido[1 ,2-a]azepin-1 0-yI)-amide *(1)5-Bromo-2,3-dihydro-benzofu ran-7-carboxylic acid (1 0-methyl-4-oxo- WO 2008/078196 PCT/IB2007/004409 95 2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) N-(1O-Ethyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-y)-2-methoxy-nicotinamide * (+/-) 2-Methoxy-N-(10-methyl-4-oxo-2-pyridin-4-yl-4,6,7,8,9,1 0-hexahyd ro pyrimido[1,2-a]azepin-1 0-yi)-nicotinamide * (+/-) 2,3-Dihydro-benzofuran-7-carboxylic acid (10-methyl-4-oxo-2-pyridin 4-yi-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 O-yl)-amide * (+/-) 2-Methoxy-N-(1 0-methyl-4-oxo-2-pyrimidin-4-yI-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide * (+/-) 2,3-Dihydro-benzofuran-7-carboxylic acid (1 0-methyl-4-oxo-2 pyrimidin-4-yi-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) 6-Fluoro-4H-benzo[1,3]dioxine-8-carboxylic acid (10-methyl-4-oxo-2 pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) 2,6-Dimethoxy-N-(1 0-methyl-4-oxo-2-pyrimidin-4-y-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide * (+/-) Pyridine-2-carboxylic acid (1 0-methyl-4-oxo-2-pyrimidin-4-yI 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 O-yl)-amide * (+/-) 4-Methoxy-pyridine-2-carboxylic acid (10-methyl-4-oxo-2-pyrimidin-4 yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) 3,6-Dimethoxy-pyridazine-4-carboxylic acid (1 0-methyl-4-oxo-2 pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) 6-Chloro-pyridine-2-carboxylic acid (10-methyl-4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide * (+/-) 8-Amino-7-chloro-2,3-dihydro-benzo[1,4]dioxine-5-carboxylic acid (1 0-methyl-4-oxo-2-pyrimidin-4-yI-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2 a]azepin-1 0-yl)-amide WO 2008/078196 PCT/1B2007/004409 96 *(1)5-Bromo-2-methylsulfanyl-pyrimidine-4-carboxylic acid (1 O-methyl-4 oxo-2-pyrimidin-4-yI-4,6 ,7,8,9, 1 O-hexahydro-pyrimido[1 ,2-a]azepin-1 O-yI) amide *(+/-) 6-Bromo-pyridine-2-carboxylic acid (1 O-methyl-4-oxo-2-pyrimidin-4-y 4,6,7,8,9,1 O-hexahydro-pyrimido[1 ,2-a]azepin-1 O-y)-amide *(+/-) 3,5-Difluoro-pyridine-2-carboxylic acid (1 O-methyl-4-oxo-2-pyrimidin 4-yl-4 ,6,7,8,9,1 0-hexahydro-pyrimidoji ,2-alazepin-1 O-y)-amide *(+/-) 2,2-Dimethyl-2,3-dihydro-benzofuran-7-carboxylic acid (1 O-methyl-4 oxo-2-pyrimidin-4-yI-4,6 ,7 ,8,9,1 I -hexahydro-pyrimido[1 ,2-a]azepin-1 O-yI) amide *(+/-) 4-Methoxy-pyridine-2-carboxylic acid (1 O-ethyl-4-oxo-2-pyrimidin-4-y 4,6,7,8,9,1 O-hexahydro-pyrimido[1 ,2-a]azepin-1 O-y)-amide *(+/-) 5-Chloro-2 ,3-d ihyd ro-benzofu ran-7-ca rboxylic acid (1 O-methyl-4-oxo 2-pyrimidin-4-yI-4 ,6 ,7,8,9, 1 O-hexahydro-pyrimido[1 ,2-alazepin-1 O-yI)-am ide *(+/-) 5-Chloro-2-methylsulfanyl-pyrimidine-4-carboxylic acid (1 O-methyl-4 oxo-2-pyri mid in-4-yI-4,6 ,7,8, 9,1 I -hexahydro-pyrimido[1 ,2-a]azepin-1 O-yI) amide *(+/-) 8-Amino-7-ch Ioro-2, 3-dihydro-benzo[1 ,4]d ioxine-5-carboxylic acid (10 ethyl-4-oxo-2-pyrimidin-4-yI-4,6 ,7,8,9, I 0-hexahyd ro-pyrimido[1 ,2-a]azepin 1 0-yI)-amide *(+/-) 3,6-Dimethoxy-pyridazine-4-carboxylic acid (10O-ethyl-4-oxo-2 pyrimidin-4-yi-4 ,6,7,8,9,1 0-hexahydro-pyrimido[1 ,2-ajazepin-1 0-yI)-amide *(+/-) 6-Fluoro-4H-benzo[1 ,3jdioxine-8-carboxylic acid (1 0-ethyl-4-oxo-2 pyrimidin-4-yI-4 ,6,7,8,9,1 0-hexahydro-pyrimido[1 ,2-a]azepin-1 0-yI)-amid *(+/-) N-(1 O-Ethyl-4-oxo-2-pyrimidin-4-yI-4,6 ,7 ,8,9,1 0-hexahydro pyrimido[1 ,2-a]azepin-1 O-yI)-2 ,6-dimethoxy-nicotinamide WO 2008/078196 PCT/IB2007/004409 97 * (+/-) N-(3-Bromo-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-2-methoxy-nicotinamide * (+/-) 6-Chloro-pyridine-2-carboxylic acid (10-ethyl-4-oxo-2-pyrimidin-4-yl 4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 O-yl)-amide N (+) 2,6-Dimethoxy-N-(4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide (-) 2,6-Dimethoxy-N-(4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,1 0-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide * (+) 2-Methoxy-N-(10-methyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide * (-) 2,6-Dimethoxy-N-(1 0-methyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide * (-) 2-Methoxy-N-(10-methyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10-hexahydro pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide M (+) 2,6-Dimethoxy-N-(1 0-methyl-4-oxo-2-pyrimidin-4-yl-4,6,7,8,9,10 hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-nicotinamide * (-) 5-Bromo-2,3-dihydro-benzofuran-7-carboxylic acid (10-methyl-4-oxo-2 pyrimidin-4-yl-4,6,7,8,9,10-hexahydro-pyrimido[1,2-a]azepin-10-yl)-amide * (+) 5-Bromo-2,3-dihydro-benzofuran-7-carboxylic acid (10-methyl-4-oxo-2 pyrimidin-4-yi-4,6,7,8,9,1 0-hexahydro-pyrimido[1,2-a]azepin-1 0-yl)-amide in the form of a free base or of an addition salt with an acid. 6. A medicament comprising as an active ingredient a substance selected from the group consisting of pyrimidone derivative represented by formula (1) or salts thereof, or a solvate thereof or a hydrate thereof according to claim 1. 7. A GSK3p inhibitor selected from the group of a pyrimidone derivative WO 2008/078196 PCT/IB2007/004409 98 represented by formula (1) or salts thereof, or a solvate thereof or a hydrate thereof according to claim 1. 8. Use of a compound according to claims 1 to 5 for the preparation of a medicament for preventive and/or therapeutic treatment of a disease caused by abnormal GSK3p activity. 9. Use of a compound according to claims 1 to 5 for the preparation of a medicament for preventive and/or therapeutic treatment of a neurodegenerative disease. 10. Use of a compound according to claim 9, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's. disease, Parkinson's disease, tauopathies, vascular dementia; acute stroke, traumatic injuries; cerebrovascular accidents, brain cord trauma, spinal cord trauma; peripheral neuropathies; retinopathies or glaucoma.
[7] 11. Use of a compound according to claims 1 to 5 for the preparation of a medicament for preventive and/or therapeutic treatment of non-insulin dependent diabetes; obesity; manic depressive illness; schizophrenia; alopecia; or cancers.
[8] 12. Use according to claim 11 wherein cancer is breast cancer, non-small cell lung carcinoma, thyroid cancer, T or B-cell leukemia or virus-induced tumors.
[9] 13. Use of a compound according to claims 1 to 5 for the preparation of a medicament for preventive and/or therapeutic treatment of malaria.
[10] 14. Use of a compound according to claims 1 to 5 for the preparation of a medicament for preventive and/or therapeutic treatment of bone diseases.
[11] 15. Use of a compound according to claims 1 to 5 for the preparation of a medicament for preventive and/or therapeutic treatment of Pemphigus vulgaris.
[12] 16. Use of a compound according to claims 1 to 5 for the preparation of a medicament for preventive and/or therapeutic treatment of neutropenia induced by cancer chemotherapy.
[13] 17. A pyrimidone derivative represented by formula (Ill), or a salt thereof, WO 2008/078196 PCT/IB2007/004409 99 or a solvate thereof or a hydrate thereof as an intermediate for the preparation of compound of formula (I) according to claim 1, wherein: R1 R7 R6 N R3 N N 0 m )o R4 R5 (Ill) R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring, the ring being optionally substituted by a C1.6 alkyl group, a C 1 . 6 alkoxy group or a halogen atom; R3 represents a hydrogen atom, a C1. 6 alkyl group or a halogen atom; R4 and R5 represent, each independently, a hydrogen atom, a C 1 . 6 alkyl group, optionally substituted by 1 to 4 substituents selected from a halogen atom, a phenyl group, a hydroxyl group or a C 1 .6alkoxy group; R6 represents a hydrogen atom, a C 1 .6 alkyl group substituted by a halogen atom or a cycloalkyle group, or a halogen atom; R7 represents a hydrogen atom or a C 1 .6 alkyl group; m represents 0 to 1; o represents 0 to 2.

类似技术:

公开号 | 公开日 | 专利标题

US8198287B2|2012-06-12|Substituted heteroaryl pyridopyrimidone derivatives

EP1957492B1|2010-11-10|Substituted bicyclic pyrimidone derivatives

EP2162443B1|2013-07-31|Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases

EP2321316B1|2014-03-12|Substituted pyrimidin-4-one derivatives

EP2238140B1|2013-07-17|Substituted heteroarylamide diazepinopyrimidone derivatives

EP2160387B1|2014-05-14|Heteroarylamide pyrimidone compounds

AU2009208726A1|2009-08-06|Substituted heteroarylamide oxazepinopyrimidone derivatives

NZ581165A|2011-09-30|Heteroarylamide pyrimidone compounds

AU2006314136A1|2007-05-24|Substituted bicyclic pyrimidone derivatives

同族专利:

公开号 | 公开日

EP1939187A1|2008-07-02|

EA200970598A1|2009-12-30|

MX2009006024A|2009-06-30|

ZA200903237B|2010-08-25|

CN101563328A|2009-10-21|

TW200831099A|2008-08-01|

NO20092373L|2009-08-28|

IL198524D0|2010-02-17|

BRPI0721058A2|2014-02-25|

US20090306088A1|2009-12-10|

US8198287B2|2012-06-12|

WO2008078196A3|2008-11-06|

IL198524A|2013-03-24|

CA2672564A1|2008-07-03|

EP2121635A2|2009-11-25|

JP2010513463A|2010-04-30|

KR20090102756A|2009-09-30|

WO2008078196A2|2008-07-03|

NZ576894A|2011-09-30|

CN101563328B|2012-03-14|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

EG13192A|1976-02-10|1982-12-31|Rhone Poulenc Ind|Nouveaux derives du dithiole-1,2 leur preparation et les compositions qui les contiennent|

US5629322A|1994-11-15|1997-05-13|Merck & Co., Inc.|Cyclic amidine analogs as inhibitors of nitric oxide synthase|

IL160397D0|2001-09-21|2004-07-25|Sanofi Synthelabo|Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido{1,2-a} pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo {1,2-a} pyrimidin-5 one derivatives for neurodegenerative disorders|

EP1460076A1|2003-03-21|2004-09-22|Sanofi-Synthelabo|Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives|

EP1460075A1|2003-03-21|2004-09-22|Sanofi-Synthelabo|Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives|EP2138494A1|2008-06-26|2009-12-30|Sanofi-Aventis|Substituted alkyl pyrimidin-4-one derivatives|

EP2138492A1|2008-06-26|2009-12-30|Sanofi-Aventis|Substituted pyrimidin-4-one derivatives|

DE102008038221A1|2008-08-18|2010-02-25|Merck Patent Gmbh|7-azaindole derivatives|

DE102008038220A1|2008-08-18|2010-02-25|Merck Patent Gmbh|oxadiazole|

WO2011107494A1|2010-03-03|2011-09-09|Sanofi|Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof|

US9199976B2|2010-06-01|2015-12-01|The University Of Queensland|Haematopoietic-prostaglandin D2 synthase inhibitors|

WO2011157827A1|2010-06-18|2011-12-22|Sanofi|Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases|

US8530413B2|2010-06-21|2013-09-10|Sanofi|Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments|

TW201215388A|2010-07-05|2012-04-16|Sanofi Sa|phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments|

TW201221505A|2010-07-05|2012-06-01|Sanofi Sa|Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament|

TW201215387A|2010-07-05|2012-04-16|Sanofi Aventis|Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament|

WO2013037390A1|2011-09-12|2013-03-21|Sanofi|6--3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors|

WO2013045413A1|2011-09-27|2013-04-04|Sanofi|6--3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors|

FR2992316A1|2012-06-22|2013-12-27|Sanofi Sa|PYRIMIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION|

EP3414239A2|2016-02-05|2018-12-19|Denali Therapeutics Inc.|Inhibitors of receptor-interacting protein kinase 1|

CN109996799A|2016-08-15|2019-07-09|拜耳作物科学股份公司|Fused bicyclic heterocycle derivative as pest control agent|

WO2018107060A1|2016-12-09|2018-06-14|Denali Therapeutics Inc.|Compounds, compositions and methods|

JP2020504743A|2016-12-22|2020-02-13|カデントセラピューティクス，インコーポレーテッド|NMDA receptor modulator and use thereof|

EP3601216A4|2017-03-21|2021-01-06|Arbutus Biopharma Corporation|Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same|

CN109748914B|2018-12-29|2021-05-25|上海珂臻医药科技有限公司|Pyridopyrimidine compound and application thereof|

法律状态:
2013-07-18| MK4| Application lapsed section 142(2)(d) - no continuation fee paid for the application|

优先权:

申请号 | 申请日 | 专利标题

EP06291995.6||2006-12-20||

EP06291995A|EP1939187A1|2006-12-20|2006-12-20|Substituted heteroaryl pyridopyrimidone derivatives|

PCT/IB2007/004409|WO2008078196A2|2006-12-20|2007-12-20|Substituted heteroaryl pyridopyrimidone derivatives|

[返回顶部]